Crrna having modified nucleotide

HK40137342APending Publication Date: 2026-09-11KYOTO UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124332
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-27
Filing Date
2026-06-04
Publication Date
2026-09-11

Smart Images

  • Figure 00000104_0000
    Figure 00000104_0000
  • Figure 00000104_0001
    Figure 00000104_0001
  • Figure 00000104_0002
    Figure 00000104_0002
Patent Text Reader

Abstract

The present invention is a precursor crRNA for a type I CRISPR-Cas system having a modified nucleotide, in which at least one nucleotide is a modified nucleotide in a region comprising the 5'arm region of a first repeat sequence, the 5 '-side stem formation region of the first repeat sequence, and the ring formation region of the first repeat sequence.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480035109.0 (22) Application Date 2024.03.26 (30) Priority Data 2023-050681 2023.03.27 JP (85) PCT International Application Entering National Phase Date 2025.11.25 (86) PCT International Application Application Data PCT / JP2024 / 012128 2024.03.26 (87) PCT International Application Publication Data WO2024 / 204287 JA 2024.10.03 (71) Applicant: National University Corporation, Kyoto University; Address: Kyoto City, Kyoto Prefecture, Japan (72) Inventors: Horita Akitsu, Kojima Yusuke, Kita Yuto (74) Patent Agency: China Patent Agency (Hong Kong) Limited, 72001; Patent Attorneys: Li Zhiqiang, Peng Chang (51) Int.Cl. C12N 15 / 11 (2006.01) C12N 5 / 10 (2006.01) C12N 15 / 09 (2006.01) C12Q 1 / 686 (2006.01) (54) Invention Title: crRNA with Modified Nucleotides (57) Abstract: This invention is a precursor crRNA, which is a type I CRISPR-Cas system precursor crRNA with modified nucleotides, wherein at least one nucleotide is a modified nucleotide in the region consisting of the 5' arm region of the first repeat sequence, the 5' side stem forming region of the first repeat sequence and the loop forming region of the first repeat sequence. Claims (2 pages), Description (49 pages), Sequence Listing (electronic publication), Drawings (40 pages) CN 121195066 A 2025.12.23 CN 1 21 19 50 66 A 1. A precursor crRNA, which is a type I CRISPR-Cas system precursor crRNA with modified nucleotides, wherein at least one nucleotide in the region formed by the 5' arm region of the first repeat sequence, the 5' stem-forming region of the first repeat sequence, and the loop-forming region of the first repeat sequence is a modified nucleotide. 2. The precursor crRNA according to claim 1, wherein at least one nucleotide in the 3' arm region of the second repeat sequence is a modified nucleotide. 3. The precursor crRNA according to claim 1 or 2, wherein the first to third nucleotides from the 5' end and the second to fourth nucleotides from the 3' end are modified nucleotides. 4. The precursor crRNA according to any one of claims 1 to 3, wherein all nucleotides in the loop-forming region of the first repeat sequence and / or the loop-forming region of the second repeat sequence are modified nucleotides.5. The precursor crRNA according to any one of claims 1 to 4, wherein the first to third nucleotides from the 5' end and the second to fourth nucleotides from the 3' end are modified nucleotides, all nucleotides constituting the 3' arm region of the first repeat sequence, the 5' arm region of the second repeat sequence, and the spacer region are ribonucleotides, and the cleavage site by Cas6 or Cas5 is unmodified. 6. The method according to any one of claims 1 to 5, wherein it has two or more spacer regions. 7. The precursor crRNA according to any one of claims 1 to 6, wherein the type I CRISPR-Cas system is a type I-E CRISPR-Cas system. 8. A precursor crRNA of a type I CRISPR-Cas system, having a 5' cap and Poly A. 9. A method for designing a precursor crRNA for an allele-specific type I CRISPR-Cas system, comprising the step of designing a precursor crRNA targeting a sequence, wherein the sequence has a deletion target site upstream of a PAM sequence adjacent to the sequence targeted by the precursor crRNA, and within the sequence targeted by the precursor crRNA, at least one allele-different base exists at a position other than the 6nth base from the downstream end of the PAM sequence or on the PAM sequence, where n is a positive integer. 10. The method of claim 9, further comprising the steps of: adjusting the length of the precursor crRNA and / or introducing mismatches into the precursor crRNA. 11. The method of claim 9 or 10, wherein the deletion target site comprises a repeat. 12. A type I CRISPR-Cas system comprising (1) and (2): (1) the precursor crRNA of any one of claims 1 to 8 or the precursor crRNA designed by the method of any one of claims 9 to 11; and (2) a proteome constituting the Cascade or a nucleic acid encoding the proteome. 13. A double-stranded nucleic acid for evaluating the activity of a type I CRISPR-Cas system, wherein one nucleic acid strand comprises, in sequence, the following (1) to (3): (1) a sequence encoding a portion of a reporter protein; (2) an insert sequence comprising a sequence targeted by crRNA or a sequence complementary to that sequence; and (3) a sequence encoding a portion of a reporter protein and different from (1), wherein (1) and (3) have repeating sequences, the sequence of (1) excluding the repeating sequence, the repeating sequence, and the sequence of (3) excluding the repeating sequence constitute the full-length sequence encoding the reporter protein, and the insert sequence of (2) has a base length of 100 to 3000. 14. A double-stranded nucleic acid for evaluating the activity of a type I CRISPR-Cas system, wherein one nucleic acid strand comprises, in sequence, the following (1) to (3): Claims 1 / 2 page 2 CN121195066 A (1) a sequence encoding a portion of a reporter protein; (2) an insertion sequence comprising a sequence targeted by crRNA and a sequence complementary to that sequence; and (3) a sequence encoding a portion of a reporter protein and different from (1), wherein (1) and (3) have repeating sequences, and the sequence of (1) excluding the repeating sequence, the repeating sequence, and the sequence of (3) excluding the repeating sequence constitute the full-length sequence encoding the reporter protein. 15. A method for producing cells with altered double-stranded DNA, comprising the step of introducing the CRISPR-Cas system of claim 12 into the cells. 16. The method of claim 15, wherein the step of introducing the CRISPR-Cas system into the cells is performed multiple times. 17. The method of claim 15 or 16, comprising the step of introducing the double-stranded nucleic acid of claim 13 or 14 into the cells. 18. The method of claim 17, wherein the introduced double-stranded nucleic acid is two or more. 19. The method of claim 17 or 18, comprising the step of sorting cells expressing the reporter protein. 20. The method according to any one of claims 15-19, wherein the cell is a pluripotent stem cell. 21. A method for analyzing the editing pattern of double-stranded DNA by a type I CRISPR-Cas system, comprising: a step of performing digital PCR using multiple PCR probes targeting deletion sites. Claims 2 / 2 Page 3 CN 121195066 A crRNA with modified nucleotides Technical Field

[0001] This invention relates to precursor crRNA (pre-crRNA) with modified nucleotides. More specifically, it relates to precursor crRNA with specific modifications, allele-specific precursor crRNA, and methods for creating cells with double-stranded DNA alterations using these precursor crRNAs. Background Technology

[0002] In recent years, the CRISPR-Cas system, which utilizes the acquired immune mechanism of eubacteria or archaea (i.e., Clustered Regularly Interspaced Short Palindromic Repeat) and CRISPR-related (Cas) proteins as its main components, has been developed into a genome editing technology, represented by gene destruction (knockout), and has been widely applied through the free design of target sequences for guide RNA. The effectors of the CRISPR-Cas system that function in the process of DNA cleavage dependent on guide RNA are broadly classified into two types: Class 1 CRISPR-Cas systems, which function by forming complexes of multiple proteins, and Class 2 CRISPR-Cas systems, which function by a single protein. Among them,The CRISPR-Cas9 system, belonging to type II of class 2, is currently the most commonly used due to its simplicity and wide range of applications. In addition, the type V CRISPR-Cas12a system is also known as another type II CRISPR-Cas system for genome editing.

[0003] On the other hand, development of genome editing using type I CRISPR-Cas systems that cut DNA using Cas proteins and Cascade complexes is also underway. For example, the type I-E CRISPR-Cas3 system developed by Osaka University (Patent Document 1) and the type I-D CRISPR-Cas10 (TiD) system developed by Tokushima University (Patent Document 2) are known. Furthermore, the inventors previously focused on a genome editing method based on RNA encoding Cas proteins and Cascade complexes, rather than on plasmid DNA that may unexpectedly integrate into the cell genome or RNPs (ribonucleoproteins) requiring protein purification, thereby successfully introducing nucleotide deletions of more than 100 bases into the target region of genomic DNA using the CRISPR-Cas3 system (Patent Document 3). Class 1 CRISPR-Cas systems require multiple proteins. On the other hand, they have a DNA cutting mechanism different from Class 2 CRISPR-Cas systems, thus inducing unique DNA deletion patterns, making them highly useful in various scenarios. The CRISPR-Cas3 system is known to induce deletions of hundreds to hundreds of thousands of bases of long DNA chains in a single direction, starting from a position tens to hundreds of bases from the guide RNA recognition sequence. Furthermore, the guide RNA recognition sequence of CRISPR-Cas3 is longer than that of the CRISPR-Cas9 system, suggesting high specificity.

[0004] Several experimental cancer cell lines commonly used in the biological and medical fields, such as HEK293T cells, have high gene introduction efficiency and are often used as model lines for genome editing. However, the gene introduction efficiency of iPS cells or primary cultured cell lines intended for regenerative medicine may not be high, and the number of cell lines selected for clinical use is inherently small, making it difficult to always select the most suitable line for gene introduction. For this reason, there is an urgent need to develop methods for achieving stable and efficient genome editing, even in cell lines with low gene introduction efficiency. From the perspective of these stable and efficient genome editing methods, it is important to further improve the usefulness of existing Class 1 CRISPR-Cas systems.

[0005] In addition, in order to make genome editing a practical technology, it is necessary to accurately analyze what kind of DNA mutations can be induced by this technology and the mutation (cutting) induction efficiency. In particular, unlike Cas9, which induces small DNA double-strand cuts, Cas3 and...Cas10 induces various long-chain deletions of different lengths, but a simple method for analyzing the proportion and length of deletion mutations produced has not yet been developed. In reality, analyzing deletion mutation patterns requires amplification of the target site using methods such as PCR. However, PCR amplification efficiency varies depending on the length of the amplified product, and deletion mutations exceeding the original amplification range (tens of kb or more) cannot be amplified, resulting in undetectable mutations. Therefore, it cannot accurately reflect the length and efficiency of the deletion mutation. While next-generation sequencing for whole-genome sequencing or pull-down sequencing of target-proximity sequences can analyze cutting patterns to some extent (Non-Patent Literature 1), the analysis is costly, and the analysis of large amounts of data requires significant technical expertise and time.

[0006] Prior Art Documents Patent Documents Patent Document 1: International Publication No. 2018 / 225858; Patent Document 2: International Publication No. 2019 / 039417; Patent Document 3: International Publication No. 2020 / 122104; Non-Patent Documents Non-Patent Document 1: Morisaka H. et al., Nat Commun. 6;10(1):5302 (2019). Summary of the Invention

[0007] Problems to be Solved by the Invention In order to further improve the usefulness of Class 1 CRISPR-Cas systems and make them more practical technologies, it is important to improve the editing efficiency of cells with low genome editing efficiency, accurately grasp the genome editing mode induced by the CRISPR-Cas system, and further expand the application methods of genome editing to meet various needs. Therefore, the problem of the present invention is to improve the editing efficiency in genome editing and to provide a method for analyzing the genome editing mode of the CRISPR-Cas system, as well as tools that can be used in the method.

[0008] In addition, the development of treatment methods for gene diseases using genome editing is also being promoted. In this type of disease, there are also dominant inheritance forms, such as myotonic dystrophy type I (DM1), which are caused by a single allele abnormality on an autosome. Current genome editing technologies primarily involve editing two alleles. Even when aiming to induce genome editing only in the target allele by targeting a region containing a target allele-specific SNP sequence, there is a problem that suitable heterozygous SNPs may not exist near the target site. Therefore, the research objective is to provide a method for single-allele-specific genome editing targeting heterozygous SNPs far from the target site.

[0009] Means for Solving the Problem To solve the above-mentioned problem, the inventors have proposed the following concept: by modifying the precursor crRNA (pre-crRNA)...Chemical modification of specific regions can inhibit RNA degradation caused by RNases and other enzymes present inside and outside the cell, potentially improving genome editing efficiency. Unmodified RNA is known to be rapidly degraded by nucleases within the cell; RNA modification can prevent this and stabilize it. However, RNA modification can alter RNA properties or secondary structure, protein interactions, and may even lead to loss of original function. Even experts cannot predict which modification to introduce at which location—this is the reality. In fact, various RNA modifications have been attempted in the Cas9 guide RNA (sgRNA or gRNA-crRNA), but it is difficult to predict which modification or location is most suitable. Furthermore, the precursor crRNA of the E. coli CRISPR-Cas3 system is a 90-base RNA consisting of two 29-base repeat sequences and a 32-base spacer sequence (Figure 3-1). There is no precedent for studying chemical modification methods when using it in mammalian cells. Furthermore, the sequence, structure, and functional characteristics of the precursor crRNA in the CRISPR-Cas3 system and the guide RNA in the CRISPR-Cas9 system are inconsistent, making it impossible to determine which modification site is optimal. Moreover, the CRISPR-Cas3 system requires processing of the precursor crRNA using Cas6, as reported in biochemical experiments. Due to the complexity of this mechanism, predicting appropriate modification sites becomes difficult.

[0010] Therefore, the inventors introduced chemical modifications into the precursor crRNA of the CRISPR-Cas3 system, exploring modification sites to enhance activity. The results showed that by adding modifications to specific regions of the precursor crRNA, genome editing efficiency was significantly improved without losing crRNA function. Surprisingly, although the precursor crRNA has an approximately symmetrical structure, left-right asymmetry was observed in the modification effect. Additionally, introducing the same modifications applied to mRNA in vivo into the precursor crRNA as those applied to mRNA in vivo also improved the activity of the precursor crRNA.

[0011] Furthermore, by modifying the single-strand annealing (SSA) reporter vector used in the CRISPR-Cas9 system, an SSA reporter vector for the type I CRISPR-Cas system was developed. Specifically, based on the DNA modification pattern of the type I CRISPR-Cas system, it was envisioned to replace the Cas9-recognized sequence in the SSA reporter vector used in the CRISPR-Cas9 system with a longer sequence. Additionally, it was noted that Cas3, as an enzyme, is a single-strand DNA cleaving enzyme, i.e., a nicking enzyme.(nickase) It was considered whether the mechanism of inducing double-strand cutting through DNA double-cutting could also be applied to this SSA reporter vector. In actual experiments constructing these SSA reporter vectors, cells exhibiting activity of the type I CRISPR-Cas system were monitored using these SSA reporter vectors. Furthermore, cells whose double-stranded DNA was altered by the CRISPR-Cas system were successfully sorted.

[0012] In addition, the inventors attempted to develop a technique for determining the length distribution and proportion of deletion mutations caused by the CRISPR-Cas system by applying droplet digital PCR (ddPCR) technology. First, the following method was conceived: designing multiple ddPCR probes at various positions around the target sequence, and directly measuring the copy number at each position in the genomic DNA of cells that have undergone genome editing. Repeated and in-depth studies were conducted, and the changes in genome editing efficiency were successfully obtained through ddPCR. Based on these insights, further repeated studies resulted in the completion of this invention.

[0013] That is, the present invention is as follows.

[0014] [1-1] A precursor crRNA, which is a type I CRISPR-Cas system precursor crRNA with modified nucleotides, wherein at least one nucleotide in the region consisting of the 5' arm region of the first repeat sequence, the 5' stem-forming region of the first repeat sequence, and the loop-forming region of the first repeat sequence is a modified nucleotide.

[0015] [1-2] The precursor crRNA according to [1-1], wherein at least one nucleotide in the 5' arm region of the first repeat sequence is a modified nucleotide.

[0016] [1-3] The precursor crRNA according to [1-1] or [1-2], wherein the first nucleotide from the 5' end is a modified nucleotide.

[0017] [1-4] The precursor crRNA according to any one of [1-1] to [1-3], wherein the first to third nucleotides from the 5' end are modified nucleotides.

[0018] [1-5] The precursor crRNA according to any one of [1-1] to [1-4], wherein all nucleotides in the 5' arm region of the first repeat sequence are modified nucleotides.

[0019] [2-1] The precursor crRNA according to any one of [1-1] to [1-5], wherein at least one nucleotide in the 3' arm region of the second repeat sequence is a modified nucleotide.

[0020] [2-2] The precursor crRNA according to [2-1], wherein the second nucleotide from the 3' end is a modified nucleotide.

[0021] [2-3] The precursor crRNA according to [2-1] or [2-2], wherein the second to fourth nucleotides from the 3' end are modified nucleotides.

[0022] [3]The precursor crRNA according to any one of [1-1] to [2-3], wherein the first to third nucleotides from the 5' end and the second to fourth nucleotides from the 3' end are modified nucleotides.

[0023] [4-1] The precursor crRNA according to any one of [1-1] to [3], wherein at least one, optionally all, nucleotides of the loop-forming region of the loop-forming region of the first repeat sequence are modified nucleotides.

[0024] [4-2] The precursor crRNA according to any one of [1-1] to [4-1], wherein at least one, optionally all, nucleotides of the loop-forming region of the second repeat sequence are modified nucleotides.

[0025] [4-3] The precursor crRNA according to any one of [1-1] to [4-2], wherein at least one, optionally all, of the modified nucleotides is a 2'-O-methylribonucleotide.

[0026] [4-4] The precursor crRNA according to any one of [1-1] to [4-3], wherein at least one nucleotide inter-bond is a phosphate thioester bond.

[0027] [4-5] The precursor crRNA according to any one of [1-1] to [4-4], wherein the nucleotide inter-bond on the 3' side of the sugar moiety having at least one or all of the modified nucleotides is a modified nucleotide inter-bond.

[0028] [4-6] The precursor crRNA according to [4-5], wherein the nucleotide inter-bond is a phosphate thioester bond.

[0029] [4-7] The precursor crRNA according to any one of [1-1] to [4-6], wherein the stem-forming region on the 3' side of the first repeat sequence and / or the stem-forming region of the second repeat sequence are all ribonucleotides.

[0030] [4-8] The precursor crRNA according to any one of [1-1] to [4-7], wherein the 3' arm region of the first repeat sequence, the 5' arm region of the second repeat sequence, and / or the 5' stem-forming region of the second repeat sequence are all ribonucleotides.

[0031] [4-9] The precursor crRNA according to any one of [1-1] to [4-8], wherein the 3' stem-forming region of the first repeat sequence, the 3' arm region of the first repeat sequence, the 5' arm region of the second repeat sequence, and the stem-forming region of the second repeat sequence are all ribonucleotides.

[0032] [4-10] The precursor crRNA according to any one of [1-1] to [4-9], wherein the spacer sequence is all ribonucleotides.

[0033] [4-11] The precursor crRNA according to any one of [1-1] to [4-10], wherein the Cas6 or Cas5 cleavage site is unmodified.

[0034] [5-1]The precursor crRNA according to any one of [1-1] to [4-11], wherein the first to third nucleotides from the 5' end and the second to fourth nucleotides from the 3' end are modified nucleotides, all nucleotides constituting the 3' arm region of the first repeat sequence, the 5' arm region of the second repeat sequence, and the spacer region are ribonucleotides, and the Cas6 or Cas5 cleavage sites are unmodified.

[0035] [5-2] The precursor crRNA according to [5-1], wherein the 3' side internucleotide bond of the sugar moiety having at least one or all of the modified nucleosides is a modified internucleotide bond.

[0036] [5-3] The precursor crRNA according to [5-1] or [5-2], wherein the 3' side bond of the ribonucleotide is a phosphodiester bond.

[0037] [6] The method according to any one of [1-1] to [5-3], having two or more spacer regions.

[0038] [7] The precursor crRNA according to any one of [1-1] to [6], wherein the type I CRISPR-Cas system is a type I-E CRISPR-Cas system, optionally a CRISPR-Cas system derived from *Escherichia coli*.

[0039] [8-1] The precursor crRNA of the type I CRISPR-Cas system having a 5' cap and Poly A.

[0040] [8-2] The precursor crRNA according to [8-1], wherein the type I CRISPR-Cas system is a type I-E CRISPR-Cas system, optionally a CRISPR-Cas system derived from *Escherichia coli*.

[0041] [8-3] The precursor crRNA according to any one of [1-1] to [7] having a 5' cap and Poly A.

[0042] [9-1] A method for designing a precursor crRNA for an allele-specific type I CRISPR-Cas system, comprising the step of designing a precursor crRNA targeting a sequence, wherein the sequence has a deletion target site upstream of a PAM sequence adjacent to the sequence targeted by the precursor crRNA, and wherein at least one base differing between alleles is present in the sequence targeted by the precursor crRNA at a position other than the 6n (n is a positive integer) base from the downstream end of the PAM sequence or on the PAM sequence.

[0043] [9-2] According to the method of [9-1], wherein the type I CRISPR-Cas system is a type I-E CRISPR-Cas system, optionally a CRISPR-Cas system derived from Escherichia coli.

[0044]

[10] According to the method of [9-1] or [9-2], comprising the steps of: adjusting the length of the precursor crRNA, and optionally...The steps of selecting the length of the spacer sequence of the precursor crRNA and / or introducing mismatches into the spacer sequence of the precursor crRNA, optionally the precursor crRNA.

[0045] [11-1] The method according to any one of [9-1] to

[10] , wherein the deletion target site comprises a repeat.

[0046] [11-2] The method according to [11-1], wherein the repeat is a triplet repeat.

[0047] [12-1] A type I CRISPR-Cas system comprising the following (1) and (2).

[0048] (1) The precursor crRNA according to any one of [1-1] to [8-3] or the precursor crRNA designed by any one of [9-1] to [11-2]; and (2) the proteome constituting the Cascade or the nucleic acid encoding the proteome.

[0049] [12-2] The CRISPR-Cas system according to [12-1] further includes (3) Cas3 and / or Cas10d or nucleic acid encoding Cas3 and / or Cas10d.

[0050]

[13] A double-stranded nucleic acid, which is a double-stranded nucleic acid used to evaluate the activity of a type I CRISPR-Cas system, wherein one nucleic acid strand contains the following (1) to (3) in sequence: (1) a sequence encoding a portion of a reporter protein, optionally a fluorescent protein; (2) an insert sequence containing a sequence targeted by crRNA or a sequence complementary to that sequence; and (3) a sequence encoding a portion of a reporter protein and different from (1), wherein (1) and (3) have repeat sequences, the sequence of (1) excluding the repeat sequence, the repeat sequence and the sequence of (3) excluding the repeat sequence constitute the full-length sequence encoding the reporter protein, and the base length of the insert sequence of (2) is 100 to 3000.

[0051] [14-1] A double-stranded nucleic acid, which is used to evaluate the activity of a type I CRISPR-Cas system, wherein one nucleic acid strand sequentially comprises the following (1) to (3): (1) a sequence encoding a portion of a reporter protein, optionally a fluorescent protein; (2) an insert sequence comprising a sequence targeted by crRNA and a sequence complementary to that sequence; and (3) a sequence encoding a portion of a reporter protein and different from (1), wherein (1) and (3) have repeat sequences, and the sequence of (1) excluding the repeat sequence, the repeat sequence, and the sequence of (3) excluding the repeat sequence constitute the full-length sequence encoding the reporter protein.

[0052] [14-2] An expression vector comprising the double-stranded nucleic acid described in

[13] or [14-1].

[0053] [15-1] A method for producing cells with altered double-stranded DNA, comprising the step of introducing the CRISPR-Cas system described in [12-1] or [12-2] into the cells.

[0054] [15-2] A method for altering the double-stranded DNA of a cell, comprising: introducing the CRISPR-Cas system described in [12-1] or [12-2] into the cell.

[0055]

[16] The method according to [15-1] or [15-2], wherein the step of introducing the CRISPR-Cas system into the cell is performed multiple times.

[0056]

[17] The method according to any one of [15-1] to

[16] , comprising: introducing the double-stranded nucleic acid described in

[13] or [14-1] (see page 5 / 49 of specification 8 CN 121195066 A) or the expression vector described in [14-2] into the cell.

[0057]

[18] The method according to

[17] , wherein the introduced double-stranded nucleic acid is two or more types.

[0058]

[19] The method according to

[17] or

[18] , comprising: sorting cells expressing reporter proteins.

[0059] [20-1] The method according to any one of [15-1] to

[19] , wherein the cell is a pluripotent stem cell, optionally an artificial pluripotent stem cell.

[0060] [20-2] The method according to any one of [15-1] to [20-1], wherein the cell is a mammalian cell, optionally a human cell.

[0061] [21-1] A method for analyzing the editing pattern of double-stranded DNA in a type I CRISPR-Cas system, comprising: a step of performing digital PCR using multiple PCR probes targeting a target site.

[0062] [21-2] The method according to [21-1], wherein the type I CRISPR-Cas system is a type I-E CRISPR-Cas system, optionally a CRISPR-Cas system derived from Escherichia coli.

[0063] [22-1] A method for extending a deletion site, comprising: a step of repeatedly introducing a type I CRISPR-Cas system into a cell.

[0064] [22-2] The method according to [22-1], wherein the type I CRISPR-Cas system is a type I-E CRISPR-Cas system, optionally a CRISPR-Cas system derived from *Escherichia coli*.

[0065] [23-1] The method according to [22-1] or [22-2], wherein the cell is a pluripotent stem cell, optionally an artificial pluripotent stem cell.

[0066] [23-2] The method according to any one of [22-1] to [23-1], wherein the cell is a mammalian cell, optionally a human cell.

[0067] [24-1] A double-stranded DNA target sequence alterer comprising the CRISPR-Cas system of [12-1] or [12-2].

[0068] [24-2] A target gene expression regulator comprising the CRISPR-Cas system of [12-1] or [12-2].

[0069]

[25] The agent according to [24-1] or [24-2] is used for the treatment of diseases.

[0070] Effects of the Invention According to the present invention, the genome editing efficiency of the type I CRISPR-Cas system can be improved, and the genome editing mode of the system can be analyzed. In addition, it is possible to provide tools for enriching genome editing cells or to perform single allele-specific genome editing. Brief Description of the Drawings

[0071] [Figure 1] shows a schematic diagram of DNA cutting performed by a type I CRISPR-Cas system. Cas3 has helicase activity and DNA nicking activity, introducing a nick in the DNA strand on the side that does not bind crRNA and the Cascade complex.

[0072] [Figure 2] shows the dynamics of the expression of the proteins constituting the Cascade complex (hereinafter, sometimes referred to as the "Cascade proteome") via mRNA. The Cascade proteome was introduced into iPS cell lines (I01s04 or I14s04) in the form of mRNA (Figure 29 of Patent Document 3) or plasmid (Figure 9d of Patent Document 3) using Lipofectamine Stem. NC represents the negative control. The expression of 2×NLS-Cas2-P2A, 2×NLS-Cas5-T2A, 2×NLS-Cas6-T2A, and 2×NLS-Cas7-P2A was analyzed in samples 8, 24, and 48 hours after transfection using anti-2A peptide antibody.

[0073] [Figure 3-1] shows a schematic diagram of the results of the study on RNA modification sites in the Cas3 precursor crRNA of Escherichia coli (E. coli). Nucleotides marked with * have 2'-O-methyl 3'-thiophosphate (MS) modification. The nucleotides with MS modification, except that the hydroxyl group at the second position of the sugar moiety is replaced with an O-methyl group, have a phosphate thioester bond between the sugar moiety of the nucleotide and the sugar moiety of the next nucleotide (as described on page 6 / 49 of the specification, CN 121195066 A, where the oxygen atom at the phosphodiester bond site is replaced by a sulfur atom (S)), and the same applies below. In the figure, the base sequence of the precursor crRNA is represented by SEQ ID NO: 168.

[0074] [Figure 3-2] shows the repeat structure of precursor crRNA other than E. coli Cas3 precursor crRNA (Source: Zheng Y et al., Front Bioeng Biotechnol. 2020 Mar 4;8:62). In the figure, the base sequences of each repeat structure are represented by SEQ ID NO: 169~174 from top to bottom.

[0075] [Figure 4-1] shows the activity changes of RNA modification sites in E. coli Cas3 precursor crRNA (lipid transfection performed by Lipofectamine Stem). The circled numbers in the figure correspond to the circled modification sites in Figure 2-1.The circled numbers. In I14s04 and I01s04 iPS cells, when the genome editing efficiency (B2M gene knockout) was measured by HLA-A / B / C staining on the cell surface with the human B2M gene as the target, high activity was found through modification of sites (1) and (4).

[0076] [Figure 4-2] shows the activity changes of RNA modification sites in E. coli Cas3 precursor crRNA (electroporation performed by 4D-Nucleofector). The circled numbers in the figure correspond to the circled numbers of the modification sites in Figure 2-1. In I01s04 iPS cells, when the genome editing efficiency was measured by HLA staining with the human B2M gene as the target, high activity was found through modification of sites (1) and (4).

[0077] [Figure 5-1] shows a schematic diagram of the additional research results of RNA modification sites in E. coli Cas3 precursor crRNA. The nucleotides marked with * have 2'-O-methyl 3'-thiophosphate (MS) modification. The arrows indicate the Cas6 cleavage sites.

[0078] [Figure 5-2] shows a schematic diagram of the additional research results on RNA modification sites in the *E. coli Cas3 precursor crRNA. Nucleotides marked with * have 2'-O-methyl 3'-thiophosphate (MS) modification. The arrows indicate the Cas6 cleavage sites.

[0079] [Figure 5-3] shows a schematic diagram of the additional research results on RNA modification sites in the *E. coli Cas3 precursor crRNA. Nucleotides marked with * have 2'-O-methyl 3'-thiophosphate (MS) modification. The arrows indicate the Cas6 cleavage sites.

[0080] [Figure 5-4] shows a schematic diagram of the additional research results on RNA modification sites in the *E. coli Cas3 precursor crRNA. Nucleotides marked with # have 2'-O-methyl (M) modification, and nucleotides marked with * have 2'-O-methyl 3'-thiophosphate (MS) modification. The arrows indicate the Cas6 cleavage sites.

[0081] [Figure 6-1] shows the activity changes of RNA modification sites in the *E. coli* Cas3 precursor crRNA as shown in Figures 5-1 to 5-4. In I14s04 iPS cells, mRNAs encoding the Cas3 and Cascade proteomes and precursor crRNAs targeting the human B2M gene were transfected with Lipofectamine Stem, and genome editing efficiency was determined by HLA-A / B / C staining. 〇 indicates an increase in activity, X indicates a decrease in activity, and N indicates a slight or no effect on activity.

[0082] [Figure 6-2] shows the results of genome editing using crRNA (B2M#1) in different iPS cell lines (1383D2). mRNAs and crRNAs expressing Cas3 and Cascade proteins were transfected with Lipofectamine Stem, and ddPCR was performed.Gene deletion efficiency was determined. n=2; error bar: standard deviation. The target sequence is the sequence shown in SEQ ID NO: 4.

[0083] [Figure 6-3] shows the activity changes of RNA modification sites shown in Figures 5-1 to 5-4 in E. coli Cas3 precursor crRNA. In 1383D2iPS cells, mRNA encoding the Cas3 and Cascade proteomes and precursor crRNAs targeting exon 45 (Ex45) of the human dystrophin (DMD) gene were transfected with Lipofectamine Stem, and the genome editing efficiency was determined by ddPCR. The target sequence is the sequence shown in SEQ ID NO: 55.

[0084] [Figure 7] shows a schematic diagram of adding a 5'-cap analog and a Poly A tail to E. coli Cas3 precursor crRNA. Precursor crRNA with an ARCA (anti-reverse cap analog) cap analog was synthesized from a plasmid with a T7 promoter encoding the precursor crRNA through in vitro transcription (IVT) reaction, and Poly A was added to the 3' end of the RNA.

[0085] [Figure 8] shows the results of TapeStation analysis using precursor crRNA with a 5'-cap and Poly A tail added to E. coli Cas3 precursor crRNA. In the IVT reaction using the mMESSAGE mMACHINE T7 Ultra transcription kit, page 7 / 49, 10 CN 121195066, PolyA crRNA (B2M#1 and B2M#4), PolyA Rxn+ is the sample with PolyA added via E. coli Poly(A) polymerase (E-PAP) and ATP, while PolyA Rxn- is the sample before PolyA addition.

[0086] [Figure 9] shows the effect produced by adding a 5'-cap analog and Poly A tail to E. coli Cas3 precursor crRNA in HEK293T cells. mRNA and precursor crRNA (B2M#4) expressing the Cas3 and Cascade proteomes were introduced into HEK293T cells using Lipofectamine 2000. A higher genome editing effect was found in precursor crRNAs with 5'-cap analogues and Poly A tails than in precursor crRNAs without these features.

[0087] [Figure 10] shows the effect produced by adding 5'-cap analogues and Poly A tails to E. coli Cas3 precursor crRNAs in strain I14s04. Lipofectamine Stem was used to introduce mRNAs and precursor crRNAs expressing the Cas3 and Cascade proteomes into strain I14s04.(B2M#1 or B2M#4). A higher genome editing effect was found in precursor crRNAs with 5'-cap analogues and Poly A tails than in precursor crRNAs without these.

[0088] [Figure 11] shows the cumulative effect of multiple Cas3 genome editing cycles. Multiple transfections with Lipofectamine Stem were performed in I01s04 and I14s04 iPS cells using mRNAs expressing the Cas3 and Cascade proteomes and Pre-both3 precursor crRNAs targeting the B2M gene (Figure 5-1). HLA staining results showed that the genome editing rate increased with the number of transfections. (I01s04: n=2, I14s04: n=3, mean ± SD) [Figure 12] shows a schematic diagram of the ddPCR-based analysis technique for Cas3 deletion induction patterns.

[0089] [Figure 13] shows the results of ddPCR analysis of Cas3 genome editing patterns in HEK293T cells. This display shows the results of Cas3 and Cascade proteome expression induced by DOX induction over several days (days 0, 1, 2, 3, or 4) with altered DOX concentrations (0.1 μM, 0.3 μM, or 1 μM). The vector pPV-C1-crRNA (B2M#1)-EF1a-G2ABApiggyBac, which stably inserts pPV-TRE3G-Bi(263+751)-EF1a-Tet3G-iPA piggyBac, and the vector pPV-TRE3G-Bi(263+751)-EF1a-Tet3G-iPA piggyBac, which regulates Cas3 and Cascade proteome expression via DOX, was used in HEK293T cells (stable line) with stably inserted pPV-C1-crRNA (B2M#1)-EF1a-G2ABApiggyBac and pPV-TRE3G-Bi(263+751)-EF1a-Tet3G-iPA piggyBac, which regulates Cas3 and Cascade proteome expression via DOX induction over several days (days 0, 1, 2, 3, or 4). The copy number of genomic DNA at approximately -3.5 kb, -1 kb, 1 kb, 10 kb, 35 kb, 50 kb, and 70 kb from the crRNA (B2M#1) target sequence was determined by ddPCR (n=3, mean ± SD). The figure shows that the genome editing mode of the CRISPR-Cas3 system varies depending on the DOX concentration. "uM" in the figure refers to "μM". The same applies below.

[0090] [Figure 14] shows the analysis results of the Cas3 genome editing mode in iPS cells using ddPCR. CiRA00213 iPS cells (stable line) with the pPV-C1-crRNA(B2M#1)-EF1a-G2AZA vector containing pPV-TRE3G-Bi(263+751)-EF1a-Tet3G-iPA vector (which can regulate the expression of the Cas3 and Cascade proteomes via DOX) inserted into the genomic DNA were analyzed by ddPCR. The distance from the crRNA (B2M#1) to the Cas3 genome editing mode varied depending on the DOX concentration.The copy numbers of genomic DNA at 50kb and 70kb showed that the genome editing mode of the CRISPR-Cas3 system varied depending on the DOX concentration (0, 0.5, 2μM) applied for 9 days.

[0091] [Figure 15] shows the deletion induction mode in the case of RNA Cas3 genome editing. The upper figure shows the results of introducing the RNA-like CRISPR-Cas3 system (1, 2, or 3 times) into I14s04iPS cells (copy numbers at approximately 1kb and 10kb from the crRNA target sequence were determined by ddPCR). The lower figure shows the results of Cas3 and Cascade proteome expression induced by DOX induction for several days (0 days, 1 day, 2 days, 3 days, or 4 days) or different DOX concentrations (0, 0.5, 2μM) in HEK293T cells and I14s04iPS cells (part of which is quoted from Figures 13 and 14 for comparison). LF Stem is an abbreviation for Lipofectamine Stem. In the figure, “ul” refers to “μl”. The same applies below.

[0092] [Figure 16] is an application example of ddPCR analysis, showing the comparison results of the induction efficiency of long-chain DNA deletion caused by Cas3 and Cas9. A. shows a schematic diagram of the experiment. In the dystrophin locus, crRNA (or sgRNA) was designed so that the regions (target regions) sandwiched by the two Cas3 crRNAs (or Cas9 sgRNAs) on different strands were (i) 1kb, (ii) 44kb, (iii) 95kb or (iv) 344kb, and ddPCR probes were designed near the center of each target region. B. is a graph showing the analysis results of the deletion frequency at both ends (near crRNA) and near the center of the target regions in (ii) to (iv) (mean ± SD, n=4, *: p<0.05). C. is a graph showing the deletion frequency near the center in (i) to (iv) (mean ± SD, n=4, *: p<0.05).

[0093] [Figure 17] is an example of the application of ddPCR analysis, showing the evaluation results of the gene deletion ratio at each site in Cas3 genome editing using 2, 4, and 11 crRNAs (or Cas9 sgRNAs). In HEK293T cells, Cas3 vector (All-in-one-Puro) and crRNA vector (or Cas9 vector (Cas9-Puro) and sgRNA vector) genes were introduced via lipid transfection using Lipofectamine 2000. In exon 45- of the dystrophin geneSeven ddPCR probes were designed in region 55 with approximately equal spacing, and the deletion frequency was analyzed (mean ± SD, n=3, *: p<0.05).

[0094] [Figure 18] shows a schematic diagram of the genome editing method for HLA-A*24:02 and B*52:01 in iPSCs (I01s04 and I14s04) from the first HLA homozygous donor from Japan. The AAG+32nt sequence was extracted and converted to AAG+X XXXXNXXXXXNXXXXXNXXXXXNXXXXXNXX, and then off-target prediction was performed using GGGenome (i.e., checking whether there are other completely consistent sites, especially whether other HLA genes are inconsistent). Then, the distance and direction were narrowed to cut the clusters of exons 1-3. The crRNA sequences (A24:02 F1 / R2 / R4, B52:01 F1 / R5 / R7) are examples. ddPCR probes and primers used to determine genome editing efficiency were designed on exon 2 of their respective genes.

[0095] [Figure 19] shows the results of PCR-based activity assays (for crRNA targeting HLA-A*A24:02). mRNA and crRNA expression vectors (pBSIIKS-U6-crRNA or pPV-C1-crRNA) expressing the Cas3 and Cascade proteomes were expressed in I14s04iPS cells using Lipofectamine Stem, and the resulting genome samples were analyzed by PCR (LA Taq HS). The presence of bands smaller than 7.7 kb indicates deletions caused by Cas3 genome editing.

[0096] [Figure 20] shows the results of ddPCR-based determination of HLA-A*24:02 and B*52:01 exon 2 deletion efficiency (single crRNA). In I14s04iPS cells, mRNAs expressing the Cas3 and Cascade proteomes and pre-both3 precursor crRNAs targeting the B2M gene, HLA-A*24:02, and B*52:01 were repeatedly transfected using Lipofectamine Stem (Figure 5-1). The recovered genomic samples were analyzed by ddPCR. The experiment using crRNA (B2M#1) served as a control (left figure).

[0097] [Figure 21] shows the results of the exon 2 deletion efficiency determination based on ddPCR (double crRNA). In the method shown in Figure 20, two types of pre-both3 precursor crRNAs targeting HLA-A*24:02 and pre-both3 precursor crRNAs targeting HLA-B*52:01 were added.

[0098] [Figure 22] shows a schematic diagram of a single-stranded annealing (SSA) reporter vector. In Cas-activated cells, the Cas3 and Cascade proteomes were analyzed by ddPCR.After the inserted sequence was cut, DNA repair mediated by SSA occurred, resulting in the expression of reporter genes with protein activity.

[0099] [Figure 23] shows the comparison results of SSA reporter activity based on the length of the inserted sequence. DOX was added to HEK293T cells that could be induced by DOX expression of Cas3 and Cascade proteomes. At the same time, an mRFP-SSA vector (mRFP expressed by SSA) containing a non-target crRNA (AAVS1#1) or target crRNA (DMPK DownSNP1T) and the gene sequence of the target DMPK (DMPK DownSNP1T) was introduced. The proportion of mRFP positive cells was determined by flow cytometry after 3 days. The lengths of the SSA insert sequences containing the target sequence were compared at approximately 0.5, 1, and 2 kb.

[0100] [Figure 24] shows approximately 6-fold enrichment of gene-deleted cells by the Puro-SSA reporter vector. HEK293T cells were used. pPV-Dual_promoter-EF1a-2xNLS-Cascade+Cas3(RD)-iCA (All-in-one mCherry)) was used as the Cas3 and Cascade protein expression vector. pPV-C1-crRNA (B2M#4)-EF1a-BA was used as the crRNA, and pHL-EF1a-EGFP-IRES-Puro-SSA (B2M-1kb)-A was used as the SSA reporter vector. From day 3 to day 5 post-transfection, 2 μg / ml of puromycin was added to the +Puro sample, and the efficiency of B2M deletion induced by genome editing was determined by HLA-A2 staining. The -Puro sample was not treated with puromycin. "ug" in the figure refers to "μg". The same applies below. Instructions 9 / 49, page 12, CN 121195066 A

[0101] [Figure 25] shows the confirmation results of the specificity of the Puro-SSA reporter vector. HEK293T cells were transfected with mCherry (an integrated Cas3 and Cascade protein expression vector), pPV-C1-crRNA (AAVS1#1)-EF1a-BA (control crRNA) or pPV-C1-crRNA (B2M#1)-EF1a-BA (control crRNA) (crRNA expression vector), and pHL-EF1a-Puro-SSA (B2M-1kb)-A (Puro-SSA reporter vector). 2 μg / ml of puromycin was added on days 2-4 post-transfection. When measuring the images and cell counts 6 days after transfection, puromycin resistance was observed through the sequence-specific activity of Cas3.

[0102] [Figure 26] shows that B2M-deficient cells were enriched approximately 10-fold using the Puro-SSA reporter vector. In Figure 25In cells, the proportion of B2M deletions was determined by HLA staining.

[0103] [Figure 27] shows a schematic diagram of the two-color SSA reporter vectors (SSA-EGFP and SSA-mRFP) and the double-cut SSA reporter vectors. Reporter vectors using long sequences (also known as "long chain sequences") as insert sequences (left) and reporter vectors using double-cut insert sequences as insert sequences (right) were fabricated.

[0104] [Figure 28] shows the results of the insertion sequence study of the two-color SSA reporter vectors (SSA-EGFP and SSA-mRFP). In HEK293T cells, the genes of the Cas3 expression vector (integrated Puro) and the crRNA expression vector (using DMDex45 and 55 as target crRNAs and B2M#1 as a non-target crRNA) were introduced via lipid transfection using Lipofectamine 2000. SSA-EGFP, which expresses EGFP via SSA, and SSA-mRFP, which expresses mRFP via SSA, were used as SSA reporter vectors. High fluorescence at the target signals, namely EGFP and mRFP, was observed when either fluorescent reporter vector and target sequence were used and introduced with appropriate crRNA (mean ± SD, n=3, *: p<0.05).

[0105] [Figure 29] shows the enrichment of genome-edited cells by dual-color SSA reporter vectors (SSA-EGFP and SSA-mRFP). Genome-edited cells were enriched when either HEK293T cells (left) or iPS cells from DMD patients (FF12020: right) were used. In HEK293T cells, genes of Cas3 vector (integrated Puro) and crRNA vector (DMDex45&55), or Cas9 vector (Cas9-Puro) and crRNA vector, and SSA reporter vectors (SSA-EGFP and SSA-mRFP) were introduced via lipid transfection using Lipofectamine 2000. In iPS cells from DMD patients, genes from Cas3 vectors (integrated Puro) and crRNA vectors (DMDex45 & 55) and SSA reporter vectors (SSA-EGFP and SSA-mRFP) were introduced via lipid transfection using Lipofectamine Stem (mean ± SD, n=3, *: p<0.05). EGFP and mRFP positive cells were sorted, and ddPCR was performed on the resulting cell genomes at the DMD Ex45, Int51, and Ex55 loci.

[0106] [Figure 30] shows the cells enriched using the dual-color SSA reporter vectors (SSA-EGFP and SSA-mRFP) from DMD patients.Sequencing results of DNA from iPS cell subclones of DMD patients. iPS cells from DMD patients (FF12020: exons 46 and 47 deleted; CiRA00458: exons 51-53 deleted; CiRA00646: exons 48-52 deleted) were transfected with Lipofectamine Stem for 24 hours, followed by a 2-day puromycin selection. EGFP / mRFP double-positive cells were then sorted using a cell sorter to obtain subclones. Genotyping was performed by PCR on the dystrophin gene exon 45-55 region, and the presence or absence of deletions was confirmed by Sanger sequencing. The results showed subclones of iPS cells with exon 45-55 regions eliminated. The base sequences in the left image are represented from top to bottom by SEQ ID NO: 175-177, and the base sequences in the right image are represented from top to bottom by SEQ ID NO: 178-180.

[0107] [Figure 31] shows the S / N ratio comparison with existing SSA reporter vectors with short insert sequences. In HEK293T cells, genes for SSA-EGFP and SSA-mRFP, which were introduced via lipid transfection using Lipofectamine 2000, were introduced into Cas3 vectors (All-in-one-Puro) and crRNA vectors (DMDex45&55 as target crRNA, B2M#1 as non-target crRNA), and SSA-EGFP and SSA-mRFP as SSA reporter vectors. The proportion of EGFP and mRFP positive cells was determined by flow cytometry. The lengths of the SSA insert sequences were 0 kb (target sequence only), 0.5 kb, 1.0 kb, and 1.7 kb.

[0108] [Figure 32] shows a list of heterozygous SNPs surrounding CTG repeats in various iPS cells from DM1 patients. The underlined sequence is the sequence of the pathogenic allele that is being targeted. ND: Not analyzed. Instruction manual, page 10 / 49, 13 CN 121195066 A

[0109] [Figure 33] shows a schematic diagram of the design method of allele-specific crRNA. The sequence X in the target sequence is a sequence that can be recognized by crRNA.

[0110] [Figure 34] shows the design results of allele-specific crRNA (DMPK CTG repeat upstream: DM1_DownSNP1C). In the figure, the base sequences are represented by SEQ ID NO: 181~184 from top to bottom. The crRNA with SNP at the 12th base (DM1_DownSNP1C_12nt) is a control crRNA that does not show allele specificity.

[0111] [Figure 35] shows the allele-specific crRNA (DM1_DownSNP1C / T and DM1_DownSNP1C_12nt)Activity evaluation results. In HPS1051 iPS cells from DM1 patients with a heterozygous SNP (C / T) of rs934739524, the pPV-Dual_promoter-EF1a-2xNLS-Cascade+Cas3(RD)-iPA vector expressing the Cas3 and Cascade proteomes and the pPV-C1-crRNA-EF11-G2ABA vector expressing each precursor crRNA were inserted into the genome (stable strain). The genomes of these cell samples were amplified by SNP-specific (allele-specific) PCR and analyzed by TapeStation. Histograms using crRNA (DownSNP1C) targeting the pathogenic allele are shown as an example (right panel).

[0112] [Figure 36] shows that subclones with CTG repeats eliminated only in the pathogenic allele can be obtained by using allele-specific crRNA (DMPK CTG repeat downstream). Single-cell cloning and genotyping were performed on the cell populations created in Figure 35. The result was the acquisition of subclones #9, #19, #20, #33, and #84 with only the CTG repeat region missing in the pathogenic allele (DownSNP1C).

[0113] [Figure 37] shows the design results of the allele-specific crRNA (upstream of the DMPK CTG repeat). In the figure, the base sequences from top to bottom are represented by SEQ ID NO: 185~188 (rs915915: UpSNP3) and SEQ ID NO: 189~193 (rs635299: UpSNP1).

[0114] [Figure 38] shows a summary of the activity evaluation results of the allele-specific crRNA (upstream of the DMPK CTG repeat). In CiRA00213 iPS cells from DM1 patients with heterozygous SNPs rs915915 (UpSNP3T / G) and rs635299 (UpSNP1T / G), pPV-C1-crRNA-EF1a-BA vectors expressing the DMPK CTG repeat-targeted precursor crRNA (as shown in Figure 37) and pPV-TRE3G-Bi(263+751)-EF1a-Tet3G-iPA vectors that can induce Cas3 and Cascade proteome expression via DOX were inserted into genomic DNA. The genome-edited genomic samples were analyzed by allele-specific nested PCR and Sanger sequencing.

[0115] [Figure 39] Details of the results using crRNA (UpSNP1T-2) (plasmid-based genome editing). Bands obtained by allele-specific nested PCR were analyzed by Sanger sequencing. Reference sequence (upper segment) and gene of occurrence were compared.The sequence alignment of the edited sample (lower segment) revealed an elongated CTG repeat and approximately 2.2 kb of other sequence deletions. At this point, the UpSNP1 (rs635299) sequence was "T", indicating that genome editing had occurred in the pathogenic allele.

[0116] [Figure 40] Details of the results using crRNA (UpSNP1T). Plasmid-based genome editing was performed, and the bands obtained by allele-specific nested PCR were analyzed using Sanger sequencing.

[0117] [Figure 41] Details of the results using crRNA (UpSNP3T). Plasmid-based genome editing was performed, and the bands obtained by allele-specific nested PCR were analyzed using Sanger sequencing.

[0118] [Figure 42] Details of the results using crRNA (UpSNP1T). RNA-based Cas3 genome editing was performed, and the bands obtained by allele-specific nested PCR were analyzed using Sanger sequencing.

[0119] [Figure 43] Details of the results using crRNA (UpSNP3T). RNA-based Cas3 genome editing was performed, and cells were isolated to approximately 10 cells / well. Bands obtained from these samples by allele-specific PCR were analyzed by Sanger sequencing (UpSNP3T well #62).

[0120] [Figure 44] Results of CTG repeat removal by allele-specific double Cas3 (Example 1). RNA-based Cas3 genome editing was performed, and bands obtained by allele-specific nested PCR were analyzed by Sanger sequencing.

[0121] [Figure 45] Results of CTG repeat removal by allele-specific double Cas3 (Example 2). RNA-based Cas3 genome editing was performed, and bands obtained by allele-specific nested PCR were analyzed by Sanger sequencing.

[0122] [Figure 46] Results of CTG repeat removal by allele-specific double Cas3 (Example 2). Plasmid-based Cas3 genome editing was performed, and the bands obtained by allele-specific nested PCR were analyzed by Sanger sequencing.

[0123] [Figure 47] shows the results of removing CTG repeats by allele-specific double Cas3 (Example 3). RNA-based Cas3 genome editing was performed, and cells were isolated to approximately 10 cells / well. The bands obtained from these samples by allele-specific PCR were analyzed by Sanger sequencing (UpSNP3T×AGGDownSNP2C well #57).

[0124] [Figure 48] shows a schematic diagram of the allele-specific evaluation method using a two-color SSA reporter vector (left).And the analysis results (right). 1 μM DOX was added to HEK293T stable cells that could express the Cas3 and Cascade proteome by DOX. The crRNA expression vector pPV-C1-crRNA-EF1a-BA (non-target: DMD#20, target: DownSNP1-C / T), mRFP SSA vector (pPV-EF1a-mRxxFP-iPA), and EGFP SSA vector (pPV-EF1a-EGxxFP-iPA) were simultaneously transfected using Lipofectamine 2000. The proportion of mRFP and EGFP positive cells was determined by flow cytometry 3 days later. The insertion sequence of the SSA vector contained the sequence of DownSNP1-T / C (rs934739524 heterozygous SNP).

[0125] [Figure 49] shows a schematic diagram of a method to improve the specificity of allele-specific crRNA.

[0126] [Figure 50] shows the adjustable specificity based on crRNA length. HEK293T stable cells expressing the Cas3 and Cascade proteome via DOX were supplemented with 1 μM DOX. The cells were simultaneously transfected with the crRNA expression vector pPV-C1-crRNA-EF1a-BA (non-target: AAVS1#1, target: DownSNP1-C), the mRFP SSA vector (pPV-EF1a-mRxxFP-iPA), and the EGFP SSA vector (pPV-EF1a-EGxxFP-iPA) using Lipofectamine 2000. Three days later, the proportions of mRFP and EGFP positive cells were determined by flow cytometry. The mRFP SSA vector used an insert sequence containing DownSNP1-T (rs934739524 heterozygous SNP-T), and the EGFP SSA vector used an insert sequence containing DownSNP1-C. The crRNA (DownSNP1-C 32nt) had the same sequence as the standard crRNA (DownSNP1-C).

[0127] [Figure 51] shows the modulometry of specificity by introducing intentional mismatches. Experimental conditions were the same as in Figure 50. The crRNA (DownSNP1-C 0MM) had the same sequence as the ordinary crRNA (DownSNP1-C). Since the data for crRNA (AAVS1#1) and crRNA (DownSNP1-C 0MM) were determined in the same batch as in Figure 50, the data are referenced from Figure 50.

[0128] [Figure 52] shows a schematic diagram of the results of additional studies on RNA modification sites in the E. coli Cas3 precursor crRNA based on protein structure. Nucleotides marked with # have 2'-O-methyl (M) modification, and nucleotides marked with + have 3'-phosphate thioester modification.(PS) modification, nucleotides marked with * have 2'-O-methyl 3'-thiophosphate (MS) modification. Arrows indicate Cas6 cleavage sites.

[0129] [Fig. 53] shows the activity changes in E. coli Cas3 precursor crRNA caused by RNA modification sites shown in Fig. 52. In I14s04iPS cells, mRNA expressing Cas3 and Cascade proteins, and B2M#1 crRNA (with chemical modifications corresponding to those in Fig. 52) were transfected, and the KO efficiency of the B2M gene was determined by HLA-A, B, and C staining. "Both sides 3" is a precursor crRNA with the same modification as Pre-both3. The same applies below.

[0130] [Fig. 54] shows the activity changes in E. coli Cas3 precursor crRNA caused by RNA modification sites shown in Fig. 52. In I14s04iPS cells, mRNA expressing Cas3 and Cascade proteins, and B2M#1 crRNA (with chemical modifications corresponding to those in Figure 52) were transfected, and the KO efficiency of the B2M gene was determined by ddPCR.

[0131] [Figure 55] shows a schematic diagram of the additional research results on RNA modification sites in E. coli Cas3 precursor crRNA based on protein structure. Nucleotides marked with # have 2'-O-methyl (M) modification, nucleotides marked with + have 3'-phosphothiophosphate (PS) modification, and nucleotides marked with * have 2'-O-methyl 3'-phosphothiophosphate (MS) modification. Arrows indicate Cas6 cleavage sites.

[0132] [Figure 56] shows the changes in activity of E. coli Cas3 precursor crRNA caused by RNA modification sites shown in Figure 52. (Instructions for Use 12 / 49 pages 15 CN 121195066 A) In I14s04iPS cells, mRNA expressing Cas3 and Cascade proteins and B2M#1 crRNA (with chemical modifications corresponding to those in Figure 52) were transfected. The KO efficiency of the B2M gene was determined by HLA-A, B, and C staining.

[0133] [Figure 57] In I14s04iPS cells, mRNA expressing Cas3 and Cascade proteins and Pre-both3 precursor crRNA targeting HLA-A*24:02 and B*52:01 were transfected multiple times using Lipofectamine Stem (Figure 5-1). The recovered genomic samples were analyzed by ddPCR. “Double A24 F1 & B52 R5” indicates tandem precursor crRNA with MS modification at both ends.

[0134] [Figure 58] Schematic diagram showing examples of chemical modification of tandem precursor crRNA. Because Cas3 precursor crRNA is processed by Cas6, it can be tandemly linked with more than two target recognition sequences as shown in the figure. In this case, modifications such as those involving three bases at both ends can be performed.

[0135] [Figure 59] shows the evaluation results of the Puro-SSA vector in 1383D4 iPS cells. 1.5 × 10⁵ cells were seeded in 12-well plates and transfected with mRNA expressing Cas3 and Cascade proteins, B2M#1 crRNA (MS modified at both ends for 3 bases), or pHL-EF1a-Puro-SSA(B2M#1)-A or pHL-EF1a-Puro-SSA(B2M#1)-2A-EGFP-A as the Puro-SSA reporter vector. Puro-based selection was performed at a concentration of 0.3 or 0.5 μg / ml on days 2-3 post-transfection. After cell recovery, the proportion of HLA-A, B, and C negative cells was determined by HLA-A, B, and C staining. Typical flow cytometry results and quantitative plots are shown (n=2). The results showed that B2M knockout cells were enriched approximately 2-4 times. Detailed Embodiments

[0136] 1. Precursor crRNA with Modified Nucleotides The present invention provides a type I CRISPR-Cas system precursor crRNA (precursor crRNA) with modified nucleotides. Specifically, a precursor crRNA (hereinafter, sometimes referred to as "the modified crRNA of the present invention") is provided, wherein at least one (e.g., two, three, four, five, six, seven, eight, nine, ten or more) nucleotide is a modified nucleotide in the region consisting of the 5' arm region of the first repeat sequence, the 5' side region of the stem-forming region of the first repeat sequence (hereinafter, sometimes referred to as "5' side stem-forming region"), and the loop-forming region of the first repeat sequence.

[0137] In addition, as shown in the following examples, it is demonstrated that genome editing efficiency can be improved by adding a cap or cap analog to the 5' end of the precursor crRNA and adding a Poly A sequence to the 3' end in the same manner as the modification of mRNA in vivo. Therefore, in another aspect of the present invention, a precursor crRNA of a type I CRISPR-Cas system having a 5' cap and Poly A is provided (hereinafter, sometimes referred to as "the 5' cap crRNA of the present invention"). Hereinafter, the term "crRNA of the present invention" is sometimes used to collectively refer to "the modified crRNA of the present invention" and "the 5' cap crRNA of the present invention".

[0138] Type I CRISPR-Cas systems are known to include six types, A to F. Any type of system can be used as the crRNA of the present invention as long as it has an arm region and a stem-loop forming region. Among them, precursor crRNAs of types I-E (especially types I-E from Escherichia coli) or types I-D (especially types I-D from Microcystis aeruginosa) are preferred. Cas (CRISPR-related) proteins encoding Cas1, Cas2, and the Cascade complex are present near the CRISPR.The Cas operon of proteins. In the I-A to I-F types of Cas operons, the Cascade complex is composed of proteins other than Cas3, which acts as a nuclease / helicase (Cas3 in types I-D does not have these activities, while Cas10d functions as a nuclease / helicase), and Cas1, Cas2, and Cas4, which participate in the cleavage of exogenous genes upon acquisition of immunity. Adding Cas3 (or a complex of Cas3 and Cas10d) to the Cascade complex enables the same DNA recognition and cleavage functions as Cas9 or Cas12a in type II CRISPR-Cas systems.

[0139] Types I-A, I-B, and I-D are relatively abundant in archaea, while types I-C, I-E, and I-F are relatively abundant in eubacteria. Type I-A has been analyzed in species such as *S. solfataricus* and *T. tenax*. Type I-B has been analyzed in species such as *Haloferax volcanii*. Type I-C has been analyzed in species such as *B. halodurans*. Type I-D has been analyzed in species such as *Microcystis aeruginosa*. Type I-E has been analyzed in species such as *Escherichia coli*. Type I-F has been analyzed in species such as *Pseudomonas aeruginosa*, *Escherichia coli*, and *P. atospeticum*. In types I-E, Cse1 (aka: CasA, Cas8e), Cse2 (aka: CasB, Cas11), Cas7 (aka: CasC, Cas4), Cas5 (aka: CasD), and Cas6 (aka: CasE) form a cascade complex in a 1:2:6:1:1 ratio relative to one crRNA molecule. In types I-D, Cas7, Cas5 (Csc1), and Cas6 form a cascade complex in a 6:1:1 ratio relative to one crRNA molecule. In type I-D CRISPR-Cas systems, GTA, GTC, and GTT can be used as protospacer adjacent motifs (PAM) sequences, while in type I-E CRISPR-Cas systems, ATG, AAG, AGG, GAG, TAG, and AAA can be used. Additionally, TCN (where N is A, T, G, or C) can be used in Type I-A CRISPR-Cas systems, while TTC can be used in Type I-B CRISPR-Cas systems.ACT, TAA, TAT, TAG, CAC, etc., can be used in I-C type CRISPR-Cas systems, and NTTC (where N is A, T, G, or C) can be used in I-F type CRISPR-Cas systems, and CC, etc. In this specification, unless otherwise specified, the base sequence is described along the 5' to 3' direction.

[0140] In type I-A CRISPR-Cas systems, the Cascade complex is composed of Cas8a1, Csa5 (Cas11), Cas5, Cas6, and Cas7. In type I-B CRISPR-Cas systems, the Cascade complex is composed of Cas8b1, Cas5, Cas6, and Cas7. In type I-C CRISPR-Cas systems, the Cascade complex is composed of Cas8c, Cas5, and Cas7. In type I-F CRISPR-Cas systems, the Cascade complex is composed of Csy1 (Cas8f), Csy2 (Cas5), Cas6, and Csy3 (Cas7). In type I-G CRISPR-Cas systems, the Cascade complex is composed of Cst1 (Cas8a1), Cas5, Cas6, and Cst2 (Cas7). Hereinafter, the Cas3, Cas10d, and Cascade proteomes are sometimes collectively referred to as "Cas proteins".

[0141] In the type I CRISPR-Cas system, a precursor crRNA having a structure consisting of a repeating sequence and a target recognition region (spacer region) as shown in Figure 3-1 (in the presence of multiple spacer sequences, repeat, spacer region 1, repeat, spacer region 2, repeat, (hereinafter repeated)) is cleaved by Cas6 (in the case of types I-A, B, D~E) or Cas5 (in the case of type I-C) to become mature crRNA. In this specification, "precursor crRNA" refers to RNA that has at least a repeat, a spacer region 1, and a repeat, and is cleaved by Cas6 or Cas5 in the cell to become a functional crRNA. Figure 3-1 shows type I-E precursor crRNAs of E. coli consisting of a repeat, a spacer region 1, and a repeat. Figure 3-2 illustrates the repeating structure of other types of precursor crRNAs (Source: Zheng Y et al., Front Bioeng Biotechnol. 2020 Mar 4;8:62). The target recognition region sequence (hereinafter sometimes called the "spacer sequence") is originally a sequence from exogenous DNA inserted during natural adaptation and can be designed based on the target DNA sequence. In the presence of one spacer region, the precursor crRNA typically contains the 5' arm region of the first repeat sequence (corresponding to Figure...).The regions in Figure 3-1 consisting of nucleotides 1-5 (GUGUU), the stem-loop region of the first repeat sequence (corresponding to the region consisting of nucleotides 6-21 (CCCCGCGCCAGCGGGG (SEQ ID NO: 1))), the 3' arm region of the first repeat sequence (corresponding to the region consisting of nucleotides 22-29 (AUAAACCG)) in Figure 3-1), the spacer region (corresponding to the region consisting of nucleotides 30-61 (XXXXXNXXXXXNXXXXXNXXXXXNXXXXXNXX)) of the second repeat sequence, the 5' arm region of the second repeat sequence (corresponding to the region consisting of nucleotides 62-66 (GUGUU)) in Figure 3-1, the stem-loop region of the second repeat sequence (corresponding to the region consisting of nucleotides 67-82 (CCCCGCGCCAGCGGGG)) of the second repeat sequence, and the 3' arm region of the second repeat sequence (corresponding to the region consisting of nucleotides 83-90 (AUAAACCG)) in Figure 3-1. Another example of a precursor crRNA with two spacer regions is shown in Figure 58. Figure 58 shows a precursor crRNA that, in addition to containing the 5' arm region of the first repeat sequence, the stem-loop forming region of the first repeat sequence, the 3' arm region of the first repeat sequence, the first spacer region (target sequence 1), the 5' arm region of the second repeat sequence, the stem-loop forming region of the second repeat sequence, and the 3' arm region of the second repeat sequence, also contains the second spacer region (target specification page 14 / 49 17 CN 121195066 A sequence 2), the 5' arm region of the third repeat sequence, the stem-loop forming region of the third repeat sequence, and the 3' arm region of the third repeat sequence. When using a precursor crRNA with multiple spacer regions like this, multiple regions can be modified by making the sequences of the spacer regions different.

[0142] The type I Cascade complex forms a complex with the crRNA (hereinafter, sometimes referred to as the "Cascade-crRNA complex"). Then, the Cascade-crRNA complex unwinds a portion of the double-stranded DNA containing the PAM and target sequences, forming a structure called the R loop, which then binds. At this point, the Cascade-crRNA complex itself undergoes a structural change, binding to the Cas3 protein (a complex of Cas3 and Cas10d in the I-D type). The Cas3 protein (Cas10d in the I-D type) possesses both DNA nicking and DNA helicase activities, introducing a nick into the non-target strand (the strand where the target recognition region of the crRNA has not been complementary (hybridized)). In the type I CRISPR-Cas3 system, PAM is present on the non-target strand; typically, PAM is located on the non-target strand.A nick is introduced at the upstream (5' side) site of the sequence, followed by a tangling reaction by helicase, resulting in a deletion upstream of the PAM sequence. Therefore, unless otherwise specified in this specification, the "target sequence" is the sequence targeted by the precursor crRNA, crRNA, or guide RNA, also known as the protospacer sequence, which is the sequence adjacent to the 3' side of the PAM on the non-target strand where the PAM is located. The target sequence is the same as the sequence of the target sequence recognition region (sometimes called the "spacer sequence") present in the crRNA (wherein, U in the RNA sequence is changed to T in the DNA sequence).

[0143] In the type I CRISPR-Cas system, there are bases in every 6 bases that the crRNA cannot recognize on the target sequence and do not contribute to sequence specificity. If the bases of the crRNA that do not contribute to the recognition of the target sequence are set as X, and the bases that contribute to the recognition of the target sequence are set as N (A, T, G, or C), then for example, 5'-NNNNNXNNNNNXNNNNNXNNNNNXNNNN-3' can be used as the target sequence. Even if the spacer sequence of crRNA is 100% inconsistent with the target sequence, it will still bind and can undergo target DNA cleavage mediated by Cas3 or Cas10d. Therefore, crRNA with a spacer sequence having at least one (e.g., two, three, four, five or more) bases substituted, deleted, added and / or inserted in the base sequence portion represented by N above can also be used in this invention. Thus, "homologous sequence" not only includes sequences that are completely identical to the target sequence (e.g., the target sequence), but also includes sequences with at least one (e.g., two, three, four, five or more) bases substituted, deleted, added and / or inserted.

[0144] The target sequence can be appropriately selected according to the purpose. Specific target sequences include, for example: sequences of the β2-microglobulin (B2M) gene and its regulatory region (e.g., sequences shown in SEQ ID NO: 4 or 5), sequences of the human leukocyte antigen (HLA) gene and its regulatory region (e.g., sequences shown in any one of SEQ ID NO: 6-38), sequences of the dystrophin (DMD) gene and its regulatory region (e.g., sequences shown in any one of SEQ ID NO: 55-68), sequences of the DMPK gene and its regulatory region (e.g., sequences shown in any one of SEQ ID NO: 39-53), sequences of the AAVS1 (adeno-associated virus integration site 1) region (e.g., sequences shown in SEQ ID NO: 54), repetitive sequences and their adjacent sequences, etc. Examples of HLA genes include: HLA-A gene, HLA-B gene, HLA-C gene, HLA-E gene, HLA-F gene, HLA-G gene, HLA-DRA gene, etc.HLA-DRB gene, HLA-DPA gene, HLA-DPB gene, HLA-DQA gene, HLA-DQB gene, etc. It is known that each HLA gene exhibits sequence diversity. For example, in the HLA-A gene, due to differences in its amino acid or base sequences, there are multiple HLA types such as HLA-A02 or HLA-A27. Examples of repetitive sequences include: sequences with three repeated bases such as "CTG", "CGG", "CAG", "GAA", "CCTG", and "TTTCA".

[0145] In another aspect of the present invention, a precursor crRNA is also provided, which targets any one of the sequences shown in SEQ ID NO: 4-68. These precursor crRNAs can also be used in combination with multiple precursor crRNAs that target the same gene or target exon. In addition, these precursor crRNAs can be wild-type precursor crRNAs or precursor crRNAs other than wild-type. These precursor crRNAs can be provided in the form of kits or formulations (such as therapeutic agents, reagents, etc.). Instruction manual 15 / 49 pages 18 CN 121195066 A

[0146] The precursor crRNA before the introduction of modified nucleotides can be wild-type precursor crRNA, as long as it maintains the ability to recognize the target sequence and recruit cascades. In at least one region of the 5' arm region of the first repeat sequence, the stem-loop forming region of the first repeat sequence, the 3' arm region of the first repeat sequence (equivalent to the 5' handle region of the mature crRNA), the spacer region, the 5' arm region of the second repeat sequence, the stem-loop forming region of the second repeat sequence, and the 3' arm region of the second repeat sequence (e.g., the 5' arm region of the first repeat sequence and / or the 3' arm region of the second repeat sequence), compared with the wild-type precursor crRNA, at least one (e.g., two, three, four, five or more) bases can be substituted, deleted, added and / or inserted. Such precursor crRNAs are sometimes referred to as "mutant precursor crRNAs" in this specification. In cases with two or more spacer regions, at least one (e.g., two, three, four, five, or more) bases may be substituted, deleted, added, and / or inserted in at least one of the regions other than those described above (e.g., the second spacer region (target sequence 2), the 5' arm region of the third repeat sequence, the stem-loop forming region of the third repeat sequence, and the 3' arm region of the third repeat sequence, compared to the wild-type precursor crRNA. Such precursor crRNAs are also included in "mutant precursor crRNAs." When adding or deleting bases in the stem-loop forming regions, it is preferable to perform base additions in a manner that maintains the stem structure (typically, with complementary two-base units).The addition or deletion of nucleotides, etc.

[0147] There is no particular limitation on the length of the spacer sequence and target sequence of the type 1 CRISPR-Cas system. For example, 30 to 45 nucleotides can be listed. In the case of types I-C, I-E and I-F, 32 to 33 nucleotides are preferred. In the case of types I-A, I-B and I-D, 34 to 44 nucleotides are preferred.

[0148] In this specification, "modified nucleotide" refers to a nucleotide other than a ribonucleotide in which at least one of the constituent elements of a ribonucleotide is modified. The constituent elements of a nucleotide include a sugar moiety (such as ribose), a base and a phosphate group. A modified nucleotide has a modification at at least one site (especially the sugar moiety) in the sugar moiety, the base and the phosphate group. In addition, a nucleoside with a modification at at least one site in the sugar moiety and the base is also called a "modified nucleotide". In this specification, "modified nucleotide" may also be appropriately referred to as "modified nucleoside". Additionally, "modification" can be exemplified by, for example, substitution, addition, and / or deletion of the constituent elements and / or nucleoside bonds, and substitution, addition, and / or deletion of atoms and / or functional groups in the constituent elements and / or nucleoside bonds. In this specification, modified nucleotides also include deoxyribonucleotides as natural nucleotides. The modified nucleotides contained in the modified crRNA of the present invention may be only one type or multiple types.

[0149] Examples of natural bases include: adenine, cytosine, guanine, thymine, and uracil. Examples of modified bases after modification of the base include, for example, 5-methylcytosine, 5-fluorocytosine, 5-bromocytosine, 5-iodocytosine, or N4-methylcytosine; N6-methyladenine or 8-bromoadenine; and N2-methylguanine or 8-bromoguanine, but are not limited to these.

[0150] Examples of modifications to the sugar moiety include: 2'-O-methoxyethyl modification of the sugar moiety, 2'-O-methyl modification of the sugar moiety, 2'-fluorine modification of the sugar moiety, and cross-linking at the 2' and 4' positions of the sugar moiety (nucleotides having this cross-linking structure are BNAs). Preferably, 2'-O-methyl modification of the sugar moiety is preferred. In this case, a portion (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) of the nucleotides contained in the modified crRNA of the present invention may be nucleotides with 2'-O-methyl modification (i.e., 2'-O-methylribonucleotides), or all of them may be 2'-O-methylribonucleotides. Examples of BNAs include: locked artificial nucleic acids (LNAs), 2'-O,4'-C-ethylene cross-linked nucleic acids (ENAs), etc. More specifically, examples of BNAs include BNAs having the following nucleoside structures.

[0151] [Chemical Formula 1] Specification 16 / 49 pages 19 CN 121195066 AIn the formula, R represents a hydrogen atom, an alkyl group with 1 to 7 carbon atoms that can form a branch or ring, an alkenyl group with 2 to 7 carbon atoms that can form a branch or ring, an aryl group with 3 to 12 carbon atoms that may contain heteroatoms, an aryl group having an aryl moiety with 3 to 12 carbon atoms that may contain heteroatoms, or a protecting group of an amino group synthesized from nucleic acids. Preferably, R is a hydrogen atom, methyl, ethyl, n-propyl, isopropyl, phenyl, or benzyl, and more preferably, R is a hydrogen atom or methyl. The bases are natural bases or modified bases.

[0152] Some (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) or all of the internucleotide bonds present in the modified crRNA of the present invention can be bonds other than phosphodiester bonds. Examples of bonds other than phosphodiester bonds (hereinafter sometimes referred to as "modified nucleoside bonds") include, but are not limited to, thiophosphate bonds, thiophosphate diester bonds, phosphotriester bonds, methylphosphonate bonds, methylthiophosphonate bonds, boranophosphate bonds, and aminophosphate bonds. In one embodiment, the 3' and / or 5' side nucleoside bonds (preferably 3' side nucleoside bonds) of the sugar moiety having a modification (e.g., 2'-O-methyl modification) are preferably modified nucleoside bonds (preferably thiophosphate bonds). In a preferred embodiment of the invention, the precursor crRNA providing all the 3' side phosphodiester bonds of the modified nuclei is a thiophosphate bond. The modified nucleoside bonds contained in the modified crRNA of the present invention can be only one type or multiple types.

[0153] In one embodiment of the modified crRNA of the present invention, at least one (e.g., two, three, four, five or more) of the modified nucleotides is preferably present in the 5' arm region of the first repeat sequence, and all nucleotides in the 5' arm region may be modified nucleotides. In this case, at least one (e.g., two, three, four, five, six, seven, eight or more) nucleotide in the 3' arm region of the second repeat sequence may be a modified nucleotide. In a preferred embodiment, the first nucleotide from the 5' end of the modified crRNA of the present invention is a modified nucleotide, and the second nucleotide from the 3' end is also a modified nucleotide. More preferably, the precursor crRNA in which the first to third nucleotides from the 5' end (corresponding to GUG in Figure 3-1) are all modified nucleotides, and the second to fourth nucleotides from the 3' end (corresponding to ACC in Figure 3-1) are all modified nucleotides. Additionally, in the loop-forming regions of the first and second repeat sequences, at least one (e.g., two, three, four, or more) or all of the nucleotides may be modified.Modified nucleotides. In this specification, the Mth nucleotide (M is a positive integer) from the 5' end refers to the Mth nucleotide in the 3' end direction when the nucleotide located at the 5' end is the first one in Figure 3-1. Additionally, although there are cases where a leader sequence is assigned to the 5' side of the precursor crRNA, in this case the position is determined according to the sequence other than the leader sequence. Similarly, the Mth nucleotide (M is a positive integer) from the 3' end refers to the Mth nucleotide in the 5' end direction when the nucleotide located at the 3' end is the first one.

[0154] As shown in the examples, no improvement in genome editing by introducing modified nucleotides was found in the 3' side region (also called the "3' side stem-forming region") of the stem-forming portion of the first repeat sequence and the stem-forming portion of the second repeat sequence. Therefore, these regions may or may not contain modified nucleotides; from a cost perspective, it is preferable to not contain modified nucleotides (i.e., all ribonucleotides). Furthermore, it was unexpectedly shown that the genome editing efficiency decreased by introducing modified nucleotides in the 3' arm region of the first repeat sequence, the 5' arm region of the second repeat sequence, and the 5' stem-forming region of the second repeat sequence. Therefore, it is preferable that these regions do not contain modified nucleotides. Thus, in one embodiment of the invention, the 3' arm region of the first repeat sequence, the 5' arm region of the second repeat sequence, and the 5' stem-forming region of the second repeat sequence of the modified crRNA of the present invention are composed solely of ribonucleotides, and the 3' stem-forming region of the first repeat sequence and the stem-forming region of the second repeat sequence may also be composed solely of ribonucleotides. Regarding the spacer sequence, at least one nucleotide (e.g., two, three, four, five, six, seven, eight, or more) can be a modified nucleotide, and in one embodiment, all are ribonucleotides. Additionally, the modified crRNA of the present invention typically has a phosphodiester bond on the 3' side of the ribonucleotide.

[0155] In type I-E CRISPR-Cas systems, during genome editing, the precursor crRNA is cleaved intracellularly into mature crRNA, which may be important for its activation. Therefore, the sites cleaved with Cas6 or Cas5 (specifically, the phosphodiester bond between the 3' terminal nucleotide of the stem-forming region of the first repeat sequence and the 5' terminal nucleotide of the 3' arm region of the first repeat sequence, and the phosphodiester bond between the 3' terminal nucleotide of the stem-forming region of the second repeat sequence and the 5' terminal nucleotide of the 3' arm region of the second repeat sequence) and / or the nucleotides adjacent to these sites (especially the 3'-side nucleotides) are preferably not modified.

[0156] In this specification, the 5' cap includes not only 7-methylguanosine (m7G) found in natural mRNA, but also its analogues (e.g., ARCA (anti-reverse cap analogue) with the OH group at the 3' position of the sugar of m7G methylated). PolyThe length of A is not particularly limited. In mammals, Poly A, consisting of 200 to 250 adenines, is usually added. Therefore, it is typical to have more than 10 (e.g., 20, 30, 40, 50 or more) or less than 300 (e.g., 250, 240, 230, 220, 210, 200 or less) Poly A.

[0157] One or more (e.g., 1, 2, 3, 4 or more) functional molecules can be bound to the crRNA of the present invention. The functional molecules are typically bound to the 5' end and / or the 3' end. In addition, the binding between the crRNA of the present invention and the functional molecules can be direct binding or indirect binding mediated by other substances. However, the functional molecules are preferably directly bound to the oligonucleotides via covalent bonds, ionic bonds, hydrogen bonds, etc. In addition, covalent bonds are more preferred from the perspective of obtaining a more stable binding. In addition, the functional molecules can bind to the crRNA via cleavable linker groups. For example, the functional molecules can be linked via disulfide bonds. Furthermore, only one functional molecule may be used, or multiple molecules may be used in combination.

[0158] The above-mentioned functional molecules are only required to impart the desired function to the crRNA of the present invention, and there is no particular limitation on the structure of the "functional molecule". Examples of desired functions include: labeling function, purification function, delivery function, etc. Examples of molecules that impart labeling function include: compounds of fluorescent dyes (Cy3, Alexa, etc.), fluorescent proteins, luciferase, etc. Examples of molecules that impart purification function include: compounds of biotin, avidin, His-tagged peptide, GST-tagged peptide, FLAG-tagged peptide, etc. As molecules that impart delivery functions, examples include: amino acid peptides P007 and B peptides (HaiFang Yin et al., Human Molecular Genetics, Vol. 17 (24), 3909-3918 (2008)), m3G-CAP (Pedro M. D. Moreno et al., Nucleic Acids Res., Vol. 37, 1925-1935 (2009)), TAT peptides, N-acetylgalactosamine (GalNAc), lipids such as cholesterol and fatty acids (e.g., vitamin E (tocopherol, tocotrienol), vitamin A and vitamin D); fat-soluble vitamins such as vitamin K (e.g., acylcarnitine); intermediate metabolites such as acyl-CoA; glycolipids, glycerides and their derivatives or analogs.

[0159] The crRNA of the present invention can be produced by chemical synthesis or by in vitro transcription (IVT).Furthermore, crRNA expressed in vivo (E. coli or mammalian cultured cells) can also be purified. Examples of chemical synthesis methods include, for instance, methods using nucleoside phosphoramide and solid-phase carriers. Additionally, by using chemically modified nucleoside phosphoramide (e.g., 2'-O-methylated phosphoramide of the sugar moiety, GalNAc phosphoramide, etc.), modified nucleotides can be introduced at any base site in the crRNA sequence.

[0160] In the IVT method, for example, single-stranded RNA can be synthesized from DNA encoding a precursor crRNA linked under the regulation of the T7 promoter using T7 RNA polymerase; however, by containing a 5' cap in the reaction solution, a precursor crRNA with a 5' cap structure can be synthesized. Moreover, by containing modified nucleoside triphosphates in the reaction solution, a precursor crRNA containing modified nucleotides can be synthesized. Furthermore, Poly A can be added by reacting Poly A polymerase with the crRNA. Alternatively, by first linking Poly T to the DNA encoding the aforementioned precursor crRNA, a precursor crRNA with added Poly A can also be synthesized via IVT.

[0161] A 5' cap can also be added to the precursor crRNA by chemical synthesis. For example, as described in Abe N et al., ACS Chem Biol. 17(6):1308-1314 (2022), a 5' cap can be added to the precursor crRNA by reacting the imidazole activator of m7G diphosphate with the precursor crRNA prepared by chemical synthesis in an organic solvent (e.g., dimethyl sulfoxide). Therefore, precursor crRNAs with a further addition of a 5' cap and Poly A to the modified crRNA of the present invention can also be used appropriately. Alternatively, the desired precursor crRNA can be obtained by specifying the base sequence and the modification site or type and ordering from the manufacturer. Hereinafter, precursor crRNAs other than wild-type containing mutant nucleotides, 5' cap structures, 3' Poly A, etc., as in the crRNA of the present invention, will also be referred to as "artificial precursor crRNAs". Artificial precursor crRNAs may be precursor crRNAs with added regions not found in wild-type precursor crRNAs.

[0162] The DNA encoding the precursor crRNA can be designed, for example, to contain a sequence of bases homologous to the target sequence (i.e., a spacer sequence) encoding the precursor crRNA, and chemically synthesized using a DNA / RNA synthesizer.

[0163] 2. The design method of allele-specific precursor crRNA is shown in Figure 33. In the type I CRISPR-Cas system, there are bases that cannot be recognized by crRNA in every 6 bases within the target sequence (bases shown as N in Figure 33). Therefore, precursor crRNAs can be designed to target sequences containing heterozygous SNPs on the target sequence other than these bases. In this case, regarding the position of the heterozygous SNP, PAM is preferably close to the sequence, and more preferably located in...The seed region or its vicinity. The seed region refers to the region with high homology (typically complete homology) to the spacer sequence of the crRNA. In the E. coli CRISPR-Cas3 system, it refers to the region from the 1st to the 8th base from the downstream (3') end of the PAM sequence (Non-Patent Literature 1). The vicinity of the seed region is typically the region from the 9th to the 11th base from the downstream (3') end of the PAM sequence. In addition, a precursor crRNA can be designed to target sequences containing heterozygous SNPs in the PAM sequence. In this case, a crRNA is designed to target sequences such that a valid PAM sequence exists on the allele for which the deletion is desired (target allele) (e.g., ATG in the I-E type CRISPR-Cas system), and the corresponding sequence on the other allele becomes an invalid PAM sequence (e.g., CTG). The crRNA designed in this way is also called "allele-specific crRNA". By using a CRISPR-Cas system containing allele-specific crRNA, a deletion site can be introduced upstream (5' side) of the PAM sequence via the target allele. In addition, the deletion site that is the target of this system is also called the untargeted site.

[0164] Therefore, in another aspect of the present invention, a method for designing allele-specific precursor crRNA is provided. Specifically, a method for designing precursor crRNAs for allele-specific type I CRISPR-Cas systems (hereinafter, sometimes referred to as "the design method of the present invention") is provided, comprising the following steps: designing a precursor crRNA targeting a sequence having a deletion target site upstream (5') of a PAM sequence adjacent to the target sequence, and having at least one base (e.g., 1, 2, 3, 4, 5, or more) different from alleles at a position other than the 6n (n is a positive integer) from the terminal base of the downstream (3') side of the PAM sequence, or on the PAM sequence. The precursor crRNA designed according to the design method of the present invention can be any crRNA constituting a type I CRISPR-Cas system, without particular limitation, but preferably type I-E (especially type I-E from *Escherichia coli*) or type I-D (especially type I-D from *Microcystis aeruginosa*) precursor crRNA, more preferably type I-E precursor crRNA.

[0165] For a given locus, where multiple (usually two copies) genes are present, each of them is referred to as an allele. In this specification, "allele specificity" means targeting only a single allele (usually the allele that becomes the cause of the disease). Furthermore, "targeting only a single allele" includes not only the other allele.The scheme of not being a target at all (or being predicted to be not a target at all) also includes the scheme of the genome editing efficiency in another allele being lower than (or predicted to be lower than) the genome editing efficiency of the target allele.

[0166] "Single nucleotide polymorphism (SNP)" generally refers to a polymorphism of a single base mutation that is found in large numbers (e.g., more than 1% frequency) in the genome base sequence of a biological population. In this specification, it refers to at least one base that is different between alleles (also called "heterozygous SNP"). In the case of heterozygous SNPs of 2 or more bases, all bases may be present at a position other than the 6n (n is a positive integer) bases downstream of the PAM sequence or on the PAM sequence, or only a portion of the bases may be present at that position or on the PAM sequence. The identification of heterozygous SNPs can be performed, for example, by searching for high-frequency SNPs in an SNP database and confirming whether the SNP is also present in cells from disease patients. Examples of SNP databases mentioned above include: dbSNP, Kaviar, SNPedia, OMIM database, dbSAP, the Human Gene Mutation Database, the International HapMap Project, GWAS Central, etc. There are no particular limitations on the alleles that are the target genes in the design method of this invention; examples include alleles that cause duplication diseases, which are caused by abnormal elongation of a specific base sequence duplication (duplication sequence). Due to the abnormal number of duplications, the disease is believed to occur through mechanisms such as loss of function, gain of function, abnormal liquid-liquid phase separation, or non-classical translation of the gene product (protein or RNA). In duplication diseases, diseases with abnormal elongation of a three-base duplication sequence are known as triad diseases. Typically, triad diseases are known to occur when the number of triplet duplications is 20 or more (typically 35 or more). Regarding the shortening of such abnormally elongated repeats, in the CRISPR-Cas9 system where base recognition and DNA cleavage occur at almost the same site, it is difficult to specifically delete the repeat sequence using heterozygous SNP alleles located at distant sites. However, in the CRISPR-Cas3 system, triad diseases can be treated by inducing deletion to shorten the abnormally elongated repeats. Therefore, in one aspect of the present invention, the deletion target site is a region including the triad repeat.

[0167] Examples of the aforementioned repeat diseases include: Fragile X syndrome (repeat: CGC, pathogenic gene: FMR1), Fragile XE.Syndrome (repeated: CCG, pathogenic gene: AFF2), Friedreich ataxia (repeated: GAA, pathogenic gene: FXN), Huntington's disease (repeated: CAG, pathogenic gene: HTT), spinal bulbar muscular atrophy (repeated: CAG, pathogenic gene: AR), spinocerebellar ataxia type 1 (repeated: CAG, pathogenic gene: ATXN1), spinocerebellar ataxia type 2 (repeated: CAG, pathogenic gene: ATXN2), spinocerebellar ataxia type 3 (repeated: CAG, pathogenic gene: ATXN3), spinocerebellar ataxia type 6 (repeated: CAG, pathogenic gene: CACNA1A), spinocerebellar ataxia type 7 (repeated: CAG, pathogenic gene: ATXN7). (Instructions for use, page 20 / 49, CN 121195066, type A, repeated: CAG, pathogenic gene: ATXN7) Spinocerebellar ataxia type 17 (duplication: CAG, pathogenic gene: TBP), dentate nucleus-globus pallidus Lewy body degeneration (duplication: CAG, pathogenic gene: DRPLA), myotonic dystrophy type 1 (duplication: CTG, pathogenic gene: DMPK), fragile X-related tremor / dyskinesia syndrome (duplication: CGC, pathogenic gene: FMR1), spinocerebellar ataxia type 8 (duplication: CTG, pathogenic gene: ATXN8), spinocerebellar ataxia type 12 (duplication: CAG, pathogenic gene: PPP2R2B), Huntington's disease-like disease type 2 (duplication: CTG, pathogenic gene: JPH3), etc.

[0168] In one embodiment, the duplication disease that is the target of the design method of the present invention is myotonic dystrophy type 1 (DM1), which is known as one of the triad diseases. DM1 is a dominant genetic disorder caused by an abnormally long CTG repeat in the 3'-UTR region of the DMPK gene, occurring only in a single allele. Examples of heterozygous SNPs for DM1 include: SNP IDs from the dbSNP database: rs16939 (distance from repeat: 2.5 kb), rs915915 (distance from repeat: 1.5 kb), rs558794490 (distance from repeat: 0.8 kb), rs635299 (distance from repeat: 0.6 kb), rs934739524 (distance from repeat: 1.6 kb), and rs3745802 (distance from repeat: 2.3 kb).

[0169] Examples of the target sequences (i.e., target sequences) of the precursor crRNA produced by the design method of the present invention include: sequences containing SNP ID: rs934739524 shown in any one of SEQ ID NO: 39, 40 and 42-47; and target sequences containing SNP.The sequences shown in any of SEQ ID NOs 48-50 of ID: rs635299, the sequences shown in SEQ ID NOs 51 or 52 of the target sequence containing SNP ID: rs915915, and the sequences shown in SEQ ID NOs 53 of the target sequence containing SNP ID: rs3745802, etc.

[0170] In addition, the activity or specificity of the crRNA designed by the design method of the present invention may vary depending on the spacer sequence. Therefore, the specificity of the target allele can be improved by adjusting the crRNA and reducing the activity of non-target alleles. Examples of such adjustment methods include: shortening the length of the crRNA (e.g., deleting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotides) or intentionally introducing base mismatches at positions far from the PAM, etc. In fact, it was demonstrated in the following embodiments that as the length of the crRNA targeting the "C" of the SNP ID No: rs934739524 is shortened or the intentional mismatch is moved closer to the PAM, the activity in the target allele decreases slowly, but the specificity can be improved if the activity in the non-target allele decreases more than that in the target allele. Therefore, the design method of the present invention may include a step of adjusting the length of the precursor crRNA (in one scheme, the length of the spacer sequence) and / or a step of introducing mismatches into the precursor crRNA (in one scheme, the spacer sequence). The number of mismatches introduced may be, for example, 1 to several (e.g., 2, 3, 4, 5 or more). In the step of introducing mismatches into the precursor crRNA, allele specificity can be further adjusted by adjusting the position of the introduced mismatch.

[0171] In the design method of the present invention, it is not required to actually synthesize the precursor crRNA; it is only necessary to imagine it in one's mind. However, typically, the imagined nucleic acid is concretized in a program running on a computer (such as nucleic acid design software, graphic design tools, office software, etc.) or on paper. In addition, the designed precursor crRNA can be actually synthesized, and the allele specificity or genome editing activity of the synthesized precursor crRNA can be evaluated.

[0172] The crRNA designed according to the design method of the present invention can be a wild-type precursor crRNA or an artificial precursor crRNA containing a mutant precursor crRNA. The definitions or types of mutant nucleotides, 5' cap structures, 3' Poly A, definitions or preparation methods of each precursor crRNA, etc., are completely quoted from the contents described in "1. Precursor crRNA with modified nucleotides" above.

[0173] 3. Type I CRISPR-Cas system and its usesIn another aspect of the present invention, a type I CRISPR-Cas system comprising the crRNA of the present invention is provided. Specifically, as described on page 24 of the detailed specification (CN 121195066 A), a type I CRISPR-Cas system comprising (1) the crRNA of the present invention and (2) the Cascade proteome (in the case of type I-E, Cse1, Cse2, Cas7, Cas5, and Cas6) or nucleic acids encoding the proteome is provided (hereinafter, sometimes referred to as "the CRISPR-Cas system of the present invention"). In the CRISPR-Cas system of the present invention, (3) the Cas3 protein or nucleic acid encoding the protein may be included. Furthermore, in the case where the type I CRISPR-Cas system is a type I-D system, the CRISPR-Cas system of the present invention may include the Cas3 protein or nucleic acid encoding the protein, and the Cas10d protein or nucleic acid encoding the protein. The nucleic acid encoding the Cas protein may be RNA or DNA. The CRISPR-Cas system of the present invention is a type I CRISPR-Cas system, preferably type I-E (especially type I-E from Escherichia coli) or type I-D (especially type I-D from Microcystis aeruginosa) CRISPR-Cas system, more preferably type I-E CRISPR-Cas system. The types or definitions of type I CRISPR-Cas are as described in "1. Precursor crRNA having modified nucleotides".

[0174] The CRISPR-Cas system of the present invention can be used to alter the double-stranded DNA present in cells. Therefore, in one embodiment, a method for altering the double-stranded DNA present in cells or a method for producing cells with altered double-stranded DNA (hereinafter, sometimes referred to as "the method of the present invention") is provided, which includes the step of introducing the CRISPR-Cas system of the present invention into the cell. Examples of double-stranded DNA present in cells include, for example: chromosomal DNA, mitochondrial DNA, chloroplast DNA (hereinafter, including these, also referred to as "genomic DNA"), exogenous DNA (such as plasmid DNA, viral DNA), etc., preferably genomic DNA, especially chromosomal DNA. Additionally, in this specification, "alteration" refers to the deletion, substitution, or insertion of a nucleotide or nucleotide sequence in a DNA strand. Furthermore, alterations to genomic DNA are sometimes also referred to as "genome editing."

[0175] Cas3, Cas10d, and Cascade proteins can be fusion proteins with a heterologous protein having the desired enzymatic activity. Enzymatic activities of such heterologous proteins include, for example, deaminase activity (e.g., cytidine deaminase activity, adenosine deaminase activity).The activities of Cas3 and Cas10d include, but are not limited to, methyltransferase activity, demethylase activity, histone acetyltransferase activity, histone deacetylase activity, activator activity, transcriptional repressor activity, DNA repair activity, DNA damage activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer formation activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, photorepair enzyme activity, and glycosylase activity. In this case, the nuclease or helicase activities of Cas3 and Cas10d are not essential, so Cas3 and Cas10d can be omitted, or mutants lacking some or all of these activities can be used (e.g., the mutant with D domain H74A (dnCas3), the mutant with K320N of SF2 domain motif 1 (dhCas3), and the double mutant with S483A / T485A of SF2 domain motif 3 (dh2Cas3)).

[0176] For example, by using a fusion protein of a mutant that has lost some or all of the nuclease activity of Cas3 and a deaminase as a component of the CRISPR-Cas3 system of the present invention, precise genome editing can be performed by substituting bases without producing large deletions at the target site. For example, as described in WO2017 / 043573, without using Cas3, base changes at specific sites can also be achieved by fusing a Cascade protein (e.g., Cas6) with a deaminase (e.g., hAID, PmCDA1, etc.). In addition, DNA modification (i.e., epigenome editing) without changes in base sequence can also be achieved by using proteins with methyltransferase activity (e.g., DNA methyltransferase, histone methyltransferase, etc.), proteins with demethylase activity (e.g., DNA demethylase, histone demethylase, etc.), histone acetyltransferase, or histone deacetylase.

[0177] The DNA encoding the Cas protein is typically provided in the form of an expression vector containing the DNA. Examples of expression vectors include: retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpesviruses, Sendai viruses, and other viral vectors, plasmid vectors, addendum vectors, artificial chromosome vectors, transposon vectors (piggyBac, piggyBat, TolII), etc.

[0178] Examples of promoters used in expression vectors include: EF1α promoter, ACTB promoter, UbqC promoter, PGK promoter, CAG promoter, SRα promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (Raoult's sarcoma virus) promoter, MoMuLV (Molonni's murine leukemia virus) LTR, HIV LTR, HSV-TK (herpes simplex virus) promoter, etc.Herpesvirus thymidine kinase) promoter, etc. Among them, EF1α promoter, ACTB promoter, UbqC promoter, PGK promoter, CAG promoter, SRα promoter, etc. are preferred.

[0179] In addition to the promoter, the expression vector may also contain enhancers, terminators, IRES, 2A coding sequence enhancers, Poly A addition signals, SV40 replication origin, selection marker genes, etc., as desired. As selection marker genes, for example, drug resistance genes, fluorescent protein genes, etc. can be listed.

[0180] The expression vector can be a combination of individual expression vectors that can express each component of the CRISPR-Cas system (e.g., in the case of type I-E, each factor of Cse1 protein, Cse2 protein, Cas7 protein, Cas5 protein, Cas6 protein, Cas3 protein, crRNA, etc.), one expression vector can be modulated to express multiple of the above factors, or one expression vector can be modulated to express all of the above factors.

[0181] When multiple of the above-mentioned factors are expressed in a single expression vector, the components of the CRISPR-Cas system can be linked by induced self-cleavage 2A sequences or IRES (internal ribosome entry site) sequences having ribosome binding sites. Examples of 2A sequences include: P2A sequences from porcine teschovirus, T2A sequences from thosea asigne, F2A sequences from foot-and-mouth disease virus, and E2A sequences from equine rhinitis A virus. IRES sequences can be sequences from viruses such as encephalomyocarditis virus and foot-and-mouth disease virus, or sequences from mRNA in cells. Thus, two or more proteins can be expressed by a single mRNA.

[0182] The inventors have previously clarified that when three expression vectors are introduced—(1) two expression vectors for each of the three genes (Cse1, Cse2, Cas7, Cas5, Cas6, and Cas3) driven by one promoter, and (2) an expression vector for the precursor crRNA—genome editing can be efficiently induced even in pluripotent stem cells. Therefore, in the scheme of introducing the Cascade proteome into stem cells in the form of expression vectors, it is preferable to express the genes of each of the two to four proteins constituting the Cascade complex by one promoter, and more preferably to express the genes of each of the three constituting proteins by one promoter.

[0183] Furthermore, the inventors have previously clarified that when three expression vectors are introduced—(1) two mRNAs for each of the three constituting proteins (Cse1, Cse2, Cas7, Cas5, Cas6, and Cas3) expressed individually, and (2) wild-type precursor crRNA—genome editing can be efficiently induced even in pluripotent stem cells.In the case of RNA, genome editing can be performed efficiently even in pluripotent stem cells. Therefore, in the scheme of introducing the Cascade proteome into stem cells in the form of mRNA, for example, mRNA encoding 2 to 4 proteins constituting Cascade in polycistronic form or mRNA encoding 3 proteins constituting Cascade in polycistronic form can be used.

[0184] The inventors have previously clarified that in the scheme of introducing two expression vectors for genome editing, namely (1) a single expression vector having 2 promoters and driving each of 3 genes in the Cse1, Cse2, Cas7, Cas5, Cas6 and Cas3 genes by 1 promoter, and (2) an expression vector of precursor crRNA, the genome editing efficiency in pluripotent stem cells is very different when the transcription directions of the two promoters are in the same direction (unidirectional promoter) and when they are in opposite directions (bidirectional promoter). It has been further clarified that the genome editing efficiency is the highest when the two promoters are in opposite directions. Therefore, in the scheme of introducing the Cascade proteome into stem cells (especially pluripotent stem cells) in the form of an expression vector, an expression cassette scheme in which every 3 genes are expressed by 1 promoter (a total of 2 promoters) is particularly preferred. These 2 expression cassettes can be located on the same expression vector or on different expression vectors. The most preferred scheme is a scheme in which the 2 expression cassettes carrying 3 genes are configured in reverse on the same expression vector (bidirectional promoter).

[0185] The promoter for expressing the Cas protein can be an expression-inducible promoter. As an expression-inducible promoter, for example, a promoter that can be induced by adding or removing expression regulatory substances in the culture medium, light irradiation, temperature changes, etc., can be used as described on pages 23 / 49 of the specification, CN 121195066 A. An expression-inducible promoter can be a promoter that induces protein expression by adding expression regulatory substances in the culture medium or a promoter that induces protein expression by removing expression regulatory substances from the culture medium. Specifically, examples of expression-inducible promoters include, but are not limited to, Tet-ON / Tet-OFF promoters (induced by the addition or removal of tetracycline or its derivatives, such as doxycycline), metallothionein promoters (induced by heavy metal ions), heat shock protein promoters (induced by heat shock), and steroid-responsive promoters (induced by steroid hormones or their derivatives).

[0186] The introduction of nucleic acids (e.g., the crRNA of the present invention), expression vectors containing such nucleic acids, or proteins (e.g., Cas3, Cas10d, proteins constituting the Cascade complex (hereinafter also referred to as "Cascade proteins")) into cells can be performed by various known methods. Examples of such methods include, for instance, calcium phosphate-mediated transfection, electroporation, liposome transfection, and liposome-mediated transfection.Transfection, gene gun, microinjection, viral vector method, virus-like particle method, Agrobacterium method, Agrobacterium agroinfiltration method, PEG-calcium method, sonoporation method, lipid nanoparticle method, etc.

[0187] The CRISPR-Cas system of the present invention can be introduced into cells multiple times. In genome editing experiments using a general CRISPR-Cas9 system, due to the occurrence of deletions or mutations in the target sequence and the high risk of off-target effects, it is basically introduced only once. However, in the type I CRISPR-Cas system, although a large deletion is introduced on the PAM sequence side of the target sequence, the sequence targeted by the crRNA (i.e., the target sequence) is usually conserved. Therefore, by introducing the same crRNA multiple times in the same cell, the deletion efficiency can be improved and the deletion site can be prolonged (cumulative). It is known that the off-target efficiency in the type I CRISPR-Cas system is lower than that in the type II CRISPR-Cas system. Therefore, there is no particular limitation on the number of introductions. Typically, it is performed 2 to 10 times (e.g., 2, 3, 4 times). Furthermore, there is no particular limitation on the interval of introduction. Typically, the CRISPR-Cas system is introduced at intervals of 1 to 15 days, preferably every 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days. Additionally, when cells with the CRISPR-Cas system introduced are cryopreserved, the cells can be thawed after several days to several years, and then the CRISPR-Cas system can be introduced back into the cells.

[0188] In the case of using a CRISPR-Cas system utilizing wild-type precursor crRNA instead of the crRNA of the present invention in the CRISPR-Cas system of the present invention, the deletion efficiency can also be improved, and the deletion site can be prolonged (cumulative). Therefore, in another embodiment, a method for prolonging the deletion site is provided, which includes the step of introducing a type I CRISPR-Cas system into the cell multiple times. In such a CRISPR-Cas system, typically, it comprises (I) wild-type precursor crRNA, (II) Cas3 protein or nucleic acid encoding the protein, and (III) Cascade proteome or nucleic acid encoding the proteome. The CRISPR-Cas system is preferably a type I-E (especially type I-E from Escherichia coli) or a type I-D (especially type I-D from Microcystis aeruginosa) CRISPR-Cas system, more preferably a type I-E CRISPR-Cas system. Furthermore, in the case of type I-D, the CRISPR-Cas system may further include the Cas10d protein or the nucleic acid encoding that protein. Type I CRISPR-Cas types or definitions are as described in "1. Precursor crRNA with modified nucleotides".

[0189] DNA encoding Cas proteins can be obtained, for example, by using genomic DNA from the aforementioned bacterial species as a template and isolating the region of the ORF containing the desired Cas protein from the Cas operon via genomic PCR. Alternatively, DNA encoding Cas proteins can be cloned by synthesizing oligomeric DNA primers based on the cDNA sequence or amino acid sequence information of the protein used (e.g., information from databases such as NCBI GenBank), and amplifying it via RT-PCR using a fraction of total RNA or mRNA modulated by the cell producing the protein as a template. Examples of NCBI accession numbers for Cse1 proteins belonging to types I-E from *E. coli* include NP_417240.1, NP_417239.1, NP_417238.1, NP_417237.2, and NP_417236.1. Additionally, the NCBI accession number CN 121195066 A on page 24 / 49 of the specification for the Cas3 protein can be listed as NP_417241.1, etc. Other Cas proteins can also be obtained from NCBI GenBank or other databases. Alternatively, sequences from novel microbial species can be obtained from microbial genome data obtained through metagenomic analysis, etc., using the BLAST program.

[0190] The Cas protein only needs to maintain the function of the protein, and can be a Cas protein obtained by substituting, deleting, adding and / or inserting one or more amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) relative to the amino acid sequence recorded in the above accession number. Alternatively, it can be a Cas protein composed of an amino acid sequence that has 70% or more, preferably 80% or more, more preferably 90% or more, and even more preferably 95% or more (e.g., 96%, 97%, 98%, 99% or more) the same as the amino acid sequence recorded in the above accession number. Amino acid sequence identity can be calculated using the NCBI BLAST (National Center for Biotechnology Information Basic Local Alignment Search Tool) algorithm for homology calculation.

[0191] Cloned DNA can be digested directly or as needed by restriction enzymes, or with the addition of appropriate adapters and / or sequences encoding nuclear transfer signals (or organelle transfer signals in the case of target double-stranded DNA being mitochondrial or chloroplast DNA).Then, it is linked with Cas3, Cas10d, or Cascade proteins to modulate the DNA encoding the fusion protein. Only one organelle transfer signal containing the nuclear transfer signal may be added, or multiple signals may be added (e.g., added to both the N-terminus and C-terminus of the protein). The method for preparing the DNA encoding the precursor crRNA is as described above in "1. Precursor crRNA with modified nucleotides".

[0192] The RNA encoding Cas3, Cas10d, or Cascade proteins may be synthesized, for example, using DNA encoding Cas3, Cas10d, or Cascade proteins as a template via an IVT reaction.

[0193] Cas3, Cas10d, or Cascade proteins may also be prepared using an in vitro translation system. Alternatively, the protein may be obtained by expressing it in cells using an expression vector or the like, and then isolating and purifying the protein from the cell.

[0194] As the cells used in the method of the present invention, for example, Escherichia coli, Bacillus spp., yeast, insect cells, insects, animal cells, plant cells, etc., may be used.

[0195] Examples of Escherichia coli bacteria used include Escherichia coli K12·DH1 [Proc. Natl. Acad . Sci. USA, 60, 160 (1968)], Escherichia coli JM103 [Nucleic Acids Research, 9,309 (1981)], Escherichia coli JA221 [Journal of Molecular Biology, 120, 517 (1978)], Escherichia coli HB101 [Journal of Molecular Biology , 41 , 459 (1969)], and Escherichia coli C600 [Genetics, 39, 440 (1954)].

[0196] Examples of Bacillus bacteria used include Bacillus subtilis MI114 [Gene, 24, 255 (1983)], Bacillus subtilis 207-21 [Journal of Biochemistry, 95, 87 (1984)].

[0197] Examples of yeasts used include Saccharomyces cerevisiae AH22, AH22R, NA87-11A, DKD-5D, 20B-12, Schizosaccharomyces pombe NCYC1913, NCYC2036, and Pichia pastoris KM71.

[0198] As insect cells, for example, strained cells from the larvae of fall armyworms (Spodoptera frugiperda cells; Sf cells), MG1 cells from the midgut of the white armyworm (Trichoplusia ni), High Five™ cells from the eggs of the white armyworm, cells from the cabbage moth (Mamestra brassicae), cells from the salt marsh moth (Estigmena acrea), strained cells from silkworms (Bombyx mori N cells; BmN cells), etc., are used. As the aforementioned Sf cells, for example, Sf9 cells (ATCC CRL1711), Sf21 cells [above, In Vivo, 13, 213-217 (1977)], etc., are used.

[0199] As plant cells, suspension culture cells, callus tissue, protoplasts, leaf sections, root sections, etc., prepared from various plants (e.g., grains such as rice, wheat, and corn; economic crops such as tomatoes, cucumbers, and eggplants; horticultural plants such as carnations and lisianthus; experimental plants such as tobacco and Arabidopsis thaliana, etc.) are used.

[0200] As animal cells, cell lines such as cells isolated from organisms, cells within organisms, monkey COS-7 cells, monkey Vero cells, Chinese hamster ovary (CHO) cells, mouse L cells, mouse AtT-20 cells, mouse myeloma cells, rat GH3 cells, HeLa cells, and human FL cells are used, as well as pluripotent stem cells from humans and other mammals (mice, rats, dogs, monkeys, etc.) and primary culture cells prepared from various tissues are used. Furthermore, zebrafish embryos, Xenopus oocytes, etc., can also be used. As the animal cells used in the method of the present invention, mammals are preferred. Examples of such mammals include: rodents such as mice, rats, hamsters, and guinea pigs; primates such as humans, rhesus monkeys, cynomolgus monkeys, Japanese macaques, and chimpanzees; and cattle, horses, dogs, and cats.

[0201] Through the method of the present invention, even in pluripotent stem cells with previously low genome editing efficiency, high genome editing effects can be expected. Therefore, pluripotent stem cells are preferred as the cells used in the method of the present invention.

[0202] In this specification, "pluripotent stem cell" refers to a stem cell that has the ability to differentiate into various tissues or cells with different morphologies or functions into an organism, and can also differentiate into cells of any system of the three germ layers (endoderm, mesoderm, and ectoderm). Examples of pluripotent stem cells used in the present invention include: artificial pluripotent stem cells (induced pluripotent stem cells: iPS cells), embryonic stem cells (embryonic stem cells).Cells: ES cells), embryonic stem cells derived from cloned embryos obtained through nuclear transfer (nuclear transfer embryonic stem cells: ntES cells), multipotent germline stem cells ("mGS cells"), embryonic germline stem cells (EG cells), preferably iPS cells (more preferably human iPS cells) and ES cells (more preferably human ES cells). When the above-mentioned multipotent stem cells are ES cells or any cells derived from human embryos, the cells may be cells created by destroying the embryo or cells created without destroying the embryo, preferably cells created without destroying the embryo.

[0203] ES cells are stem cells that are pluripotent and have the ability to proliferate based on self-replication, established from the internal cell mass of (early) embryos (e.g., blastocysts) of mammals such as humans or mice. ES cells were discovered in mice in 1981 (MJ Evans and MH Kaufman (1981), Nature 292:154-156). Subsequently, ES cell lines were also established in primates such as humans and monkeys (J.A. Thomson et al. (1998), Science 282:1145-1147; J.A. Thomson et al. (1995), Proc. Natl. Acad. Sci. USA, 92:7844-7848; JA Thomson et al. (1996), Biol. Reprod., 55:254-259; JA Thomson and VS Marshall (1998), Curr. Top. Dev. Biol., 38:133-165). ES cells can be established by taking the inner cell mass from the blastocyst of a fertilized egg of the target animal and culturing the inner cell mass on a fibroblast feeder layer. Alternatively, ES cells can be established using only a single blastomer of a pre-blastocyst embryo (Chung Y. et al. (2008), Cell Stem Cell 2: 113-117), or using an arrested embryo (Zhang X. et al. (2006), Stem Cells 24: 2669-2676).

[0204] As the ES cell line used in this invention, if it is a mouse ES cell, various mouse ES cell lines established by inGenious Targeting Laboratory, RIKEN, etc. can be used, for example, and human ES cell lines established by the University of Wisconsin, NIH, RIKEN, Kyoto University, National Center for Child Health and Medical Research and other institutions ... can be used, for example, and human ES cell lines established by the University of Wisconsin, NIH, RIKEN, Kyoto University, National Center for Child Health and Medical Research and other institutions can be used, for example, and human ES cell lines can be used, for example, and human ES cell lines established by the University ofVarious human ES cell lines established by companies such as Cellartis. Specifically, examples of human ES cell lines include: CHB-1~CHB-12, RUES1, RUES2, HUES1~HUES28, etc., distributed by ESI Bio; H1, H9, etc., distributed by WiCell Research; KhES-1, KhES-2, KhES-3, KhES-4, KhES-5, SSES1, SSES2, SSES3, etc., distributed by Riken.

[0205] iPS cells are cells obtained by reprogramming mammalian somatic cells or undifferentiated stem cells by introducing specific factors (nuclear initialization factors) into them. Currently, there are various types of iPS cells. Besides the iPSCs established by Yamanaka et al. by introducing four factors—Oct3 / 4, Sox2, Klf4, and c-Myc—into mouse fibroblasts (Takahashi K, Yamanaka S., Cell, (2006) 126: 663-676), there are also iPSCs derived from human cells, established by introducing the same four factors into human fibroblasts (Takahashi K, Yamanaka S., et al. Cell, (2007) 131: 861-872.); Nanog-iPSCs, established by sorting and using Nanog expression as an indicator after introducing the above four factors (Okita , K., Ichisaka, T., and Yamanaka, S. (2007). Nature 448, 313-317.); and iPSCs produced using a method that does not contain c-Myc (Nakagawa M. ,Yamanaka S., et al. Nature Biotechnology, (2008) 26, 101-106); iPSCs established by introducing 6 factors through a virus-free method (Okita K et al. Nat. Methods 2011 May;8(5):409-12, Okita K et al. Stem Cells. 31(3):458-66.), etc. In addition, artificial pluripotent stem cells established by introducing 4 factors, OCT3 / 4, SOX2, NANOG, and LIN28, as prepared by Thomson et al. (Yu J., ThomsonJA. et al., Science (2007) 318: 1917-1920.), and artificial pluripotent stem cells prepared by Daley et al. (Park IH, DaleyGQ. et al., Nature (2007) 451: 141-146), artificial pluripotent stem cells produced by Sakurada et al. (Japanese Patent Application Publication No. 2008-307007), etc.

[0206] As artificial pluripotent stem cell lines, various iPSC lines established by NIH, RIKEN, Kyoto University, etc. can be used. For example, if it is a human iPSC strain, the following can be listed: Riken's HiPS-RIKEN-1A strain, HiPS-RIKEN-2A strain, HiPS-RIKEN-12A strain, Nips-B2 strain, etc.; Kyoto University's 253G1 strain, 253G4 strain, 1201C1 strain, 1205D1 strain, 1210B2 strain, 1383D2 strain, 1383D4 strain, 1383D6 strain, 201B7 strain, 409B2 strain, 454E2 strain, 606A1 strain, 610B1 strain, 648A1 strain, 1231A3 strain, Ff-I01s04 strain, Ff-I14s04 strain, etc.

[0207] Cells introduced with the CIRSPR-Cas system can be cultured according to known methods depending on the cell type.

[0208] For example, when culturing *Escherichia coli* or *Bacillus* spp., a liquid culture medium is preferred as the culture medium. Furthermore, the culture medium preferably contains carbon sources, nitrogen sources, and inorganic substances required for the growth of the transformant. Examples of carbon sources include glucose, dextrin, soluble starch, and sucrose; examples of nitrogen sources include ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extract, soybean meal, and potato extract; examples of inorganic substances include calcium chloride, sodium dihydrogen phosphate, and magnesium chloride. Additionally, yeast extract, vitamins, and growth factors may be added to the culture medium. The pH of the culture medium is preferably about 5 to about 8.

[0209] As a culture medium for culturing *Escherichia coli*, M9 medium [Journal of Experiments in Molecular Genetics, 431-433, Cold Spring Harbor Laboratory, New York 1972] or LB medium containing glucose and casein amino acids are preferred. If necessary, agents such as 3β-indoleacrylic acid may be added to the medium to ensure efficient promoter function. *Escherichia coli* culture is typically carried out at approximately 15 to approximately 43°C. Aeration or stirring may be performed as needed.

[0210] Bacillus spp. culture is typically carried out at approximately 30 to approximately 40°C. Aeration or stirring may be performed as needed.

[0211] As a culture medium for culturing yeast, Burkholder basal medium [Proc. Natl.] is an example.[Acad. Sci. USA, 77, 4505 (1980)] or SD medium containing 0.5% casein amino acids [Proc. Natl. Acad. Sci. USA, 81, 5330 (1984)]. The pH of the medium is preferably about 5 to about 8. The culture is usually carried out at about 20°C to about 35°C. Aeration or stirring may be performed as needed.

[0212] As a culture medium for culturing insect cells or insects, for example, a medium in which appropriate additives such as inactivated 10% bovine serum are added to Grace's Insect Medium [Nature, 195, 788 (1962)]. The pH of the medium is preferably about 6.2 to about 6.4. The culture is usually carried out at about 27°C. Aeration or stirring may be performed as needed.

[0213] As culture media for culturing animal cells, for example, the minimum essential medium (MEM) containing about 5% to about 20% fetal bovine serum is used [Science, 122, 501 (1952)], Dulbecco modified Eagle medium (DMEM) [Virology, 8, 396 (1959)], RPMI 1640 medium [The Journal of the American Medical Association, 199, 519 (1967)], 199 medium [Proceeding of the Society for the Biological Medicine, 73, 1 (1950)], etc. As culture media for culturing human iPS cells and other pluripotent stem cells, mTeSR medium, Essential-8 medium, StemFit AK03N medium, etc. are used. The pH of the culture medium is preferably about 6 to about 8. Culture is usually carried out at about 30°C to about 40°C. Aeration or stirring may be performed as needed.

[0214] MS medium, LS medium, B5 medium, etc., are used as culture media for culturing plant cells. The pH of the culture medium is preferably about 5 to about 8. Culturing is usually carried out at about 20°C to about 30°C. Aeration or stirring may be performed as needed.

[0215] In another embodiment, a target sequence alterer and a target gene expression regulator (hereinafter also referred to as "the formulation of the present invention") comprising double-stranded DNA of the CRISPR-Cas system of the present invention are also provided. These formulations can also be used to treat or prevent diseases in mammals (e.g., the aforementioned recurrent diseases, etc.). Examples of such mammals include: mice, rats, hamsters, guinea pigs.Rodents; primates such as humans, rhesus monkeys, cynomolgus monkeys, Japanese macaques, and chimpanzees; cattle, horses, dogs, cats, etc.

[0216] The formulations of the present invention can be administered to mammals orally or parenterally (e.g., subcutaneous injection, intramuscular injection, intravenous injection, local injection (topical application, topical application), intraventricular administration, intraspinal administration, intraperitoneal administration, etc.). Examples of formulations for oral administration include: solid or liquid dosage forms, specifically tablets (including sugar-coated tablets, film-coated tablets), pills, granules, powders, capsules (including soft capsules), syrups, emulsions, suspensions, etc. On the other hand, formulations for parenteral administration include, for example, topical preparations (such as ointments, creams, topical liquids, etc.), injections, suppositories, etc. Injections may include dosage forms such as intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, and intravenous drip injections.

[0217] The CRISPR-Cas system of the present invention can be formulated with any carrier, such as a pharmacologically acceptable carrier. Examples of pharmacologically acceptable carriers include: excipients such as sucrose and starch; binders such as cellulose and methylcellulose; disintegrants such as starch and carboxymethylcellulose; lubricants such as magnesium stearate and Aerosil; flavorings such as citric acid and menthol; preservatives such as sodium benzoate and sodium bisulfite; stabilizers such as citric acid and sodium citrate; suspending agents such as methylcellulose and polyvinylpyrrolidone; dispersants such as surfactants; diluents such as water and physiological saline; base waxes, etc., but are not limited to these.

[0218] When the active ingredient of the formulation of the present invention is in the form of nucleic acid, in order to promote the introduction of the nucleic acid into target cells, the formulation of the present invention may further contain a nucleic acid introduction reagent. As reagents for introducing the nucleic acid, for example, calcium chloride, calcium enrichment reagent, atelocollagen; liposomes; nanoparticles; Lipofectin, lipofectamine, DOGS (Transfectam), DOPE, DOTAP, DDAB, DHDEAB, HDEAB, polygluconine, or cationic lipids such as poly(ethyleneimine) (PEI) can be used.

[0219] 4. Single-chain annealed (SSA) reporter nucleic acid and its use In another aspect of the present invention, an SSA reporter nucleic acid for use in a type I CRISPR-Cas system is provided. Specifically, a double-stranded nucleic acid (hereinafter, sometimes referred to as "the long-chain insert nucleic acid of the present invention") is provided, which is a double-stranded nucleic acid for evaluating the activity of a type I CRISPR-Cas system, wherein one nucleic acid strand comprises, in sequence, the following (1) to (3): (1) a sequence encoding a portion of a reporter protein (i.e., a portion of a reporter gene (also called a "selection marker gene")); (2) an insert sequence containing the sequence targeted by the crRNA or a sequence complementary to that sequence; and (3)The sequence that encodes a portion of the reporter protein is different from (1). (1) and (3) have repetitive sequences. The sequences other than the repetitive sequence of (1), the repetitive sequence and the repetitive sequence of (3) constitute the full-length sequence encoding the reporter protein. The base length of the insertion sequence in (2) is 100~3000.

[0220] Alternatively, a double-stranded nucleic acid (hereinafter, sometimes referred to as "the double-cut nucleic acid of the present invention") is provided, which is a double-stranded nucleic acid for evaluating the activity of a type I CRISPR-Cas system, wherein one nucleic acid strand sequentially comprises the following (I) to (III): (I) a sequence encoding a portion of a reporter protein; (II) an insert sequence comprising a sequence targeted by crRNA and a sequence complementary to that sequence; and (III) a sequence different from (I) encoding a portion of a reporter protein, (I) and (III) having repeat sequences, the sequence other than the repeat sequence of (I), the repeat sequence, and the sequence other than the repeat sequence of (III) constitute the sequence encoding the full length of the reporter protein. Hereinafter, "the long-chain insert nucleic acid of the present invention" and "the double-cut nucleic acid of the present invention" are sometimes collectively referred to as "the SSA reporter nucleic acid of the present invention".

[0221] In the SSA reporter nucleic acid of the present invention, DNA cleavage occurs near the target sequence using a type I CRISPR-Cas system, Then a single-stranded DNA region is formed. (1) and (3), or (I) and (III) have repeating sequences, and an annealing reaction occurs between these repeating sequences, repairing the DNA damage generated in the SSA reporter nucleic acid. As a result, a sequence encoding the full length of the reporter protein is generated in the SSA reporter nucleic acid, and the protein is expressed. That is, the activity or degree of the type I CRISPR-Cas system in the cell can be evaluated by using the expression of the reporter protein or its expression level as an indicator. The SSA reporter nucleic acid of the present invention can be applied to type I CRISPR-Cas systems, preferably type I-E (especially type I-E from Escherichia coli) or type I-D (especially type I-D from Microcystis aeruginosa) CRISPR-Cas systems, more preferably type I-E CRISPR-Cas systems. Type I CRISPR-Cas types or definitions are as described in "1. Precursor crRNA with modified nucleotides".

[0222] The reporter proteins used in the SSA reporter nucleic acid of this invention include, but are not limited to, fluorescent proteins, luminescent enzymes, chromogenic enzymes, and drug-resistant proteins. Examples of fluorescent proteins include, for example, blue fluorescent proteins such as Sirius, TagBFP, and EBFP; and cyan fluorescent proteins such as mTurquoise, TagCFP, AmCyan, mTFP1, MidoriishiCyan, and CFP.Green fluorescent proteins include TurboGFP, AcGFP, TagGFP, Azami-Green (e.g., hmAG1), GFP, ZsGreen, EmGFP, EGFP, GFP2, and HyPer; yellow fluorescent proteins include TagYFP, EYFP, Venus, YFP, PhiYFP, PhiYFP-m, TurboYFP, ZsYellow, and mBanana; orange fluorescent proteins include KusabiraOrange (e.g., hmKO2) and mOrange; red fluorescent proteins include TurboRFP, DsRed-Express, DsRed2, TagRFP, DsRed-Monomer, AsRed2, and mStrawberry; and near-infrared fluorescent proteins include TurboFP602, mRFP, JRed, KillerRed, mCherry, HcRed, KeimaRed (e.g., hdKeimaRed), mRasberry, and mPlum, but are not limited to these. Examples of luminescent enzymes include: firefly luciferase, bacterial luciferase, synthetic renin luciferase, and luciferase from the spiny shrimp (Oplophorus gracilirostris) (such as NanoLuc, a registered trademark), and secretory luciferase. Examples of chromogenic enzymes include: β-galactosidase, β-glucuronidase, and alkaline phosphatase. Examples of drug resistance proteins include: kanamycin resistance protein, ampicillin resistance protein, neomycin resistance protein, puromycin resistance protein, methimazole resistance protein, and zeocin resistance protein.

[0223] In the long-chain sequence insert-type nucleic acid of the present invention, the length of the insert sequence is typically more than 100 bases (e.g., 200 bases, 300 bases, 400 bases, 500 bases or longer) and less than 3000 bases (e.g., 2500 bases, 2000 bases, 1900 bases, 1800 bases, 1700 bases or shorter), preferably 500 to 2000 bases, and more preferably 1000 to 1700 bases. In one embodiment, the length of the insert sequence is 1000 bases. The left side of Figure 27 shows a schematic diagram of an example of a long-chain sequence insert-type nucleic acid.

[0224] In the double-cut nucleic acid of the present invention, the insert sequence contains a sequence targeted by the crRNA (i.e., the target sequence) and a sequence complementary to that sequence. Therefore, since both strands of a double-stranded nucleic acid contain the target sequence, it can be said that there are two target sequences. (Instructions 29 / 49, page 32, CN 121195066 A)The sequence is configured as a palindrome. The CRISPR-Cas system functions in each strand to cause DNA cleavage (DNA cuts, etc.), thereby triggering a DNA repair reaction mediated by SSA. Additionally, a spacer sequence (hereinafter sometimes referred to as an "SSA spacer sequence") may or may not be present between the 3' end of the target sequence of the aforementioned crRNA and the 5' end of the sequence complementary to that sequence, but is preferably absent. When an SSA spacer sequence is present, its length is not particularly limited; typically it is 1 to 100 bases long, preferably 1 to 50 bases long, and more preferably 15 to 35 bases long. Therefore, in one embodiment of the present invention, in a double-cut nucleic acid, an SSA spacer sequence (typically 1 to 100 bases long) exists between the 3' end of the target sequence of the crRNA in (II) and the 3' end of the sequence complementary to that sequence. The right side of Figure 27 shows a schematic diagram of an example of a double-cut nucleic acid. In the case of double-cut nucleic acids, there is no particular limitation on the length of the inserted sequence, typically 64 bases or more (e.g., 100 bases, 150 bases, 200 bases or more) and less than 1000 bases (e.g., 800 bases, 600 bases, 400 bases or less).

[0225] In this specification, "complementary" refers to the relationship between nucleic acid bases that can form so-called Watson-Crick base pairs (natural base pairs) or non-Watson-Crick base pairs (Hoogsteen base pairs, Wobble base pairs, etc.) via hydrogen bonds. Therefore, "complementary sequence" is used in the following sense: it includes not only sequences that are completely complementary to the target sequence (e.g., the target sequence of crRNA, etc.) (i.e., hybridization without mismatches), but also sequences that can hybridize with the target sequence under strict conditions or physiological conditions of mammalian cells and contain one to several (e.g., 2, 3, 4, 5 or more) mismatches. That is, complementary strands are allowed to contain mismatches. For example, sequences that are completely complementary to the target sequence and sequences with identity of 80% or more (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more), most preferably 100%, can be listed. The identity of the base sequences in this specification can be calculated using the homology calculation algorithm NCBI BLAST.

[0226] As described above, the activity level of the type I CRISPR-Cas system can be evaluated using the SSA reporting nucleic acid of the present invention. Therefore, in another embodiment, a method for evaluating the activity level of the type I CRISPR-Cas system (hereinafter, sometimes referred to as "the evaluation method of the present invention") is provided, which includes the following steps: Step (A), introducing the target cells for evaluating the activity of the type I CRISPR-Cas system.The invention introduces the SSA reporter nucleic acid in step (A); and step (B) evaluates the activity of the type I CRISPR-Cas system by detecting or measuring the expression of reporter proteins in cells in which the SSA reporter nucleic acid was introduced in step (A).

[0227] The cells in step (A) in which the type I CRISPR-Cas system was introduced can be cells in which the type I CRISPR-Cas system (i.e., precursor crRNA or nucleic acid encoding the RNA, each Cas protein or nucleic acid encoding the protein) was introduced beforehand, cells in which the type I CRISPR-Cas system was introduced simultaneously with step (A), or cells in which the type I CRISPR-Cas system was introduced after step (A). The nucleic acid encoding the protein can be RNA or DNA. Alternatively, the cells in step (A) in which the type I CRISPR-Cas system was introduced can be cells with nucleic acids linked to Cas proteins under the regulation of expression-inducible promoters. In this case, the type I CRISPR-Cas system can be expressed at the desired time by adding or removing expression-inducing factors corresponding to each promoter in the culture medium.

[0228] When the reporter protein is a fluorescent protein, a luminescent enzyme, or a chromogenic enzyme, step (B) can be performed by detecting or measuring the fluorescence intensity, luminescence intensity, or colorimetric intensity of the cells using known methods. Alternatively, if the reporter protein is a drug-resistant protein, it can be determined by whether it survives in a culture medium containing the corresponding drug, or by adjusting the concentration of the drug in the culture medium. Alternatively, antibodies that specifically recognize the protein can be used for detection or measurement via Western blotting, immunostaining, or enzyme immunoassays (such as EIA, ELISA).

[0229] It is hypothesized that genome editing efficiency increases proportionally to the activity of the type I CRISPR-Cas system; therefore, the SSA reporter nucleic acid of the present invention can be used to enrich cells that have undergone genome editing. Therefore, in another embodiment, a cell sorting method (hereinafter, sometimes referred to as "the cell sorting method of the present invention") is provided, which includes the following steps: step (a), introducing the SSA reporter nucleic acid of the present invention into the target cell specification page 33 CN 121195066 A; and step (b), sorting cells expressing reporter proteins from the cells in which the SSA reporter nucleic acid has been introduced in step (a).

[0230] Step (b) is not particularly limited as long as cells expressing reporter proteins can be sorted. When the reporter protein is a fluorescent protein, the fluorescence can be used as an indicator to sort cells using a cell sorting instrument such as FACS (Fluorescence-Activated Cell Sorter). Alternatively, when the reporter protein is present on the cell surface, cells expressing reporter proteins can be sorted by connecting a substance (antibody, etc.) that binds to the reporter protein to magnetic beads or agarose beads.Group. In addition, when the reporter protein is a drug-resistant protein, the agent can be added to the culture medium and the surviving cells can be sorted.

[0231] The SSA reporter nucleic acid of the present invention is typically provided in the form of an expression vector containing the nucleic acid. The types of expression vectors or the types or descriptions of promoters (including expression-inducible promoters) or other components used in the vector, the SSA reporter nucleic acid of the present invention, the method of introducing the expression vector containing the nucleic acid or the Cas protein into the cell, and the types of cells used in the present invention or the cell culture method, etc., are all described in "1. Precursor crRNA with modified nucleotides" and "3. Type I CRISPR-Cas system and its use" above.

[0232] In the evaluation method and the sorting method of the present invention, the SSA reporter nucleic acid of the present invention may use only one type or two or more types. When using two or more types, for example, by using SSA reporter nucleic acids with different target sequences of crRNA and sequences encoding reporter proteins, the target recognition ability of multiple crRNAs can be evaluated in one operation or only cells that have undergone genome editing at multiple target sites can be sorted. In these cases, it is preferable to use combinations of different fluorescent colors (such as combinations of green fluorescent proteins like EGFP and red fluorescent proteins like mRFP) or combinations of different types of reporter proteins (such as combinations of fluorescent proteins and drug resistance proteins).

[0233] Alternatively, the specificity of the crRNA can be evaluated by using two or more SSA reporter nucleic acids of the present invention in the evaluation of crRNA designed according to the design method of the present invention. For example, in two SSA vectors expressing EGFP or mRFP as reporter proteins, by using an insertion sequence that has a one-base difference on the target sequence of the crRNA, it is possible to analyze which of EGFP and mRFP emits a signal preferentially. As shown in the following examples, when the SNP sequence of rs934739524 is inserted into the SSA reporter nucleic acid with EGFP and the SNP sequence of "T" is inserted into the SSA reporter nucleic acid with mRFP, and genome editing is performed using crRNAs that target each, it is shown that the EGFP signal is preferentially observed in the crRNA targeting "C", while the mRFP signal is preferentially observed in the crRNA targeting "T".

[0234] The SSA reporter nucleic acid of the present invention can be provided in the form of a kit. The kit may contain only one SSA reporter nucleic acid of the present invention, or it may contain multiple types. In addition, the kit may contain cell sorting reagents, cell culture medium, reagents for introducing cells, nucleic acids or proteins, and instructions describing the evaluation method or cell sorting method of the present invention.

[0235] 5. Analysis method for editing mode of CRISPR-Cas systemAs shown in the following embodiments, multiple droplet digital PCR (ddPCR) probes are designed at various positions around the target sequence, and the DNA copy number at each position is directly measured in the genomic DNA of cells that have undergone genome editing, thereby capturing changes in genome editing efficiency. Therefore, in another aspect of the present invention, a method for analyzing the editing pattern of double-stranded DNA based on a type I CRISPR-Cas system (hereinafter, sometimes referred to as "the analytical method of the present invention") is provided, which includes: a step of performing digital PCR using multiple PCR probes targeting deletion sites. Using the analytical method of the present invention, the editing pattern of double-stranded DNA can be easily analyzed, for example, at what proportion and what length of deletion mutation has occurred.

[0236] As mentioned above, it is known that in type I-E CRISPR-Cas systems, long chain deletions are typically introduced on the 5' side of the target sequence, and in type I-D CRISPR-Cas systems, indels (insertions / deletions) are typically introduced into or near the target site, and long chain deletions are introduced on the 5' and 3' sides of the target sequence. As a type 1 CRISPR-Cas system, the preferred type is I-E (especially type I-E from Escherichia coli, page 31 / 49, CN 121195066 A) or type I-D (especially type I-D from Microcystis aeruginosa), and more preferably type I-E CRISPR-Cas system.

[0237] In this specification, "deletion target site" refers to a site predicted to be deleted due to the introduction of the CRISPR-Cas system. In a type I CRISPR-Cas system, regions consisting of 100 or more (e.g., 1000, 10000 or more) nucleotides upstream and / or downstream of the PAM sequence can be deleted, and thus probe-primer pairs targeting these regions can be designed. In addition, when using multiple precursor crRNAs or guide RNAs, the regions surrounded by these RNA target regions also become deletion target sites.

[0238] By narrowing the spacing between probes on the target sequence of the probe, precise analysis can be performed, and on the other hand, the number of probes designed can also be increased. The probe spacing can be adjusted appropriately according to the purpose of the analysis. Typically, probes are set with a spacing of 100 to 2,000,000 bases, such as a spacing of 1,000 to 100,000 bases, or a spacing of 3,000 to 70,000 bases. Additionally, each probe is typically 5 to 40 bases long, preferably 10 to 35 bases long, and more preferably 18 to 30 bases long.

[0239] A fluorescent dye can be attached to each probe. Various fluorescent dyes are commercially available, such as 6-FAM (fluorescein), HEX, TE, and Quasar.Examples of suitable quenchers include 670, Quasar 570, Quasar 705, Pulsar 650, TET, HEX, VIC, JOE, CAL Fluor Orenge, CAL Fluor Gold, CAL Fluor Red, Texas Red, Cy, and Cy5. Additionally, each probe preferably incorporates a quencher that can quench fluorescence from the fluorescent dye. As a quencher, any quencher capable of quenching fluorescence from the fluorescent dye is acceptable; there are no particular limitations. It can be either a fluorescent or non-fluorescent dye, but from the perspective of detection accuracy, non-fluorescent dyes are preferred. Specific examples of quenchers include: Black Hole Quencher 1 (BHQ1), 6-carboxytetramethylrhodamine (TAMRA), 6-carboxy-X-rhodamine (ROX), Eclipse Dark Quencher, Iowa black FQ (IBFQ), minor groove binder (MGB), and non-fluorescent quencher (NFQ). Examples of combinations of fluorescent dyes and quenchers include, but are not limited to, combinations of 6-FAM and BHQ1, HEX and BHQ1, etc. In a preferred embodiment, the fluorescent dye is bound to the 5' or 3' end of each probe, and the quencher is bound to the opposite end.

[0240] Examples of digital PCR methods used in the present invention include, for example, droplet digital PCR (ddPCR) and chip-based digital PCR (cdPCR). Digital PCR is performed, for example, by the following steps: A reaction solution containing a probe set, a DNA sample, a PCR primer set, and DNA polymerase is set in a digital PCR apparatus. Here, the mixing ratio of each reaction solution component can be appropriately selected and optimized within a known range, and can be appropriately changed depending on the primer set or probe set used.

[0241] In the case of ddPCR, the reaction solution is prepared into tiny droplets (e.g., nanoliter size) using a water-oil emulsion. In the case of cdPCR, the reaction solution is dispensed into thousands to tens of thousands of such tiny reaction wells (e.g., well sizes of tens of micrometers) on a chip using a digital PCR device. In such a micro-divided reaction mixture, the amount of DNA sample is adjusted to include both a state containing the region of DNA to be measured (preferably about 1 copy) and a state not containing that region, and PCR is performed. At this time, a PCR amplification reaction occurs in the reaction droplets or wells containing the DNA region to be measured. At this time, due to the nuclease activity of DNA polymerase, the probe bound to the target site is cleaved, and the fluorescent dye is separated from the quencher, emitting fluorescence. According to the reading of the digital PCR device, the number of droplets or wells that detected fluorescence is measured, and thus the fluorescence can be obtained through statistical calculation.The total number of droplets or wells is used to quantify the DNA copy number. Additionally, by using two or more probe fluorescent dyes simultaneously (e.g., 6-FAM and HEX), the copy number of two or more DNA regions can be compared using the same sample (e.g., a comparison between regions predicted to have DNA deletion and regions predicted not to have DNA deletion).

[0242] In this way, the DNA deletion rate at distances from the crRNA or guide RNA can be calculated. Specifically, for example, in the case of analyzing the deletion induction pattern of Cas3 in gene X on pages 32 / 49 of the specification (CN 121195066 A), digital PCR probes and primers are designed in a manner that, starting from the crRNA target sequence, the distances in the forward direction are approximately 1 kb, 10 kb, 20 kb, and in the opposite direction, the distances are 1 kb (-1 kb), 3.5 kb (-3.5 kb). Digital PCR probes and primers are also designed in regions considered not to be within the Cas3 genome editing range (e.g., on other genes Y) used for comparison. When gene X is located on an autosome, since the cell retains two copies, approximately two copies will be obtained regardless of the measurement location without genome editing. However, when a deletion mutation is induced by Cas3, although the copy number of the comparison object (gene Y) remains approximately two copies, the copy number of gene X decreases depending on its location (e.g., at a position 1 kb from crRNA with a copy number of 1.5 copies, the copy number decreases by 25%, indicating a deletion longer than 1 kb by 25%). Since the extent of copy number reduction at any location in gene X depends on the cleavage pattern exhibited by Cas3 from the crRNA target sequence, the Cas3 deletion mutation induction pattern can be determined.

[0243] As primers that can be used for digital PCR, specifically, examples include: primers for the human B2M gene containing any one of the sequences shown in SEQ ID NO: 103, 104, 106, 107, 109, 110, 112, 113, 115, 116, 118, 119, 121, 122, 124 and 125; primers for the human HLA gene containing any one of the sequences shown in SEQ ID NO: 127, 128, 130 and 131; and primers for the human DMD gene containing SEQ ID NO: 132, 133, 135, 136, 138, 139, 141, 142, 144. Primers of any of the sequences shown, 145, 147, 148, 150, 151, 153, 154, 156, 157, 159, 160, 162, 163, 165, and 166. These primers can be used in appropriate combinations of forward and reverse primers.

[0244] As probes that can be used for digital PCR, examples include: probes for the human B2M gene containing any one of the sequences shown in SEQ ID NO: 102, 105, 108, 111, 114, 117, 120, and 123; probes for the human HLA gene containing the sequences shown in SEQ ID NO: 126 or 129; and probes for the human DMD gene containing any one of the sequences shown in SEQ ID NO: 134, 137, 140, 143, 146, 149, 152, 155, 158, 161, 164, and 167. These probes can also be used in combination of two or more.

[0245] Other embodiments of the invention also provide primers comprising the sequences shown in any one of SEQ ID NO: 103, 104, 106, 107, 109, 110, 112, 113, 115, 116, 118, 119, 121, 122, 124, 125, 127, 128, 130, 131, 132, 133, 135, 136, 138, 139, 141, 142, 144, 145, 147, 148, 150, 151, 153, 154, 156, 157, 159, 160, 162, 163, 165, and 166, and / or primers comprising SEQ ID NO: 102, 105, 108, 111, 114, 117, 120, Probes for any of the sequences shown in 123, 126, 129, 134, 137, 140, 143, 146, 149, 152, 155, 158, 161, 164, and 167. These primers and probes may be provided in the form of kits or pharmaceuticals (such as therapeutic agents, reagents, etc.).

[0246] The following examples are provided to illustrate the invention in more detail, but the invention is not limited thereto. Examples

[0247] <Materials and Methods> Ethical Approval The establishment and use of iPSCs from patients were approved by the Ethics Committees of the Graduate School of Medicine, Kyoto University and Kyoto University Hospital (Approval Nos. R0091 and G259). All patient information was kept anonymous and written informed consent was obtained.

[0248] The chemically modified precursor crRNA was prepared by commissioning Integrated DNA Technologies (IDT) to synthesize modified nucleic acid (RNA).

[0249] Instructions for the preparation of precursor crRNA with added 5' cap and Poly A, pages 33 / 49, CN 121195066 A. Transcription was performed using the Invitrogen mMESSAGE mMACHINE T7 Ultra Transcription Kit via in vitro transcription (IVT).A precursor crRNA sequence containing a 5' cap analog (ARCA) and a PolyA tail was synthesized. The template for IVT was prepared by PCR using a PCR forward primer (GAAATTAATACGACTCACTATAGGATGTGTTGTTTGTGTGATACTA; SEQ ID NO: 2) and a reverse primer (CCCGGGCtgcaggaattc; SEQ ID NO: 3) containing the T7 promoter sequence, with a plasmid (pPV-C1-crRNA-EF1a-G2ABA) containing the precursor crRNA sequence (B2M#1 or B2M#4) as the template. The 5' cap analog was introduced during T7 polymerase transcription by a mixture of cap analog and GTP at a ratio of 4:1, and the PolyA tail was added post-transcriptionally using E. coli Poly(A) polymerase (E-PAP). A leader sequence was included at the 5' end of the final precursor crRNA sequence.

[0250] The sequence targeted by the precursor crRNA used in this embodiment (target sequence) is as follows.

[0251] [Table 1-1] [Table 1-2] Specification 34 / 49 pages 37 CN 121195066 A [Table 1-3] [Table 1-4] Specification 35 / 49 pages 38 CN 121195066 A Transduction of CRISPR-Cas3 and CRISPR-Cas9 For iPSC transduction, 1.5 to 3 × 10⁵ cells were seeded in the wells of a 12-well plate coated with iMatrix-511 or iMatrix-511 silk. The next day, a total of 1000 to 2000 ng of plasmid DNA or RNA was transfected into the cells using 2 to 4 μL of Lipofectamine Stem (Thermo Fisher Scientific). When HEK293T cells are transduced, 2 × 10⁵ cells are seeded in 12-well plates or 1 × 10⁶ cells are seeded in 6-well plates. The following day, 1000–2000 ng of plasmid DNA or RNA is transfected using 4–8 μL of Lipofectamine 2000 (Thermo Fisher Scientific). CRISPR-Cas3 and Cascade proteome expression plasmids were prepared using pPV-Dual_promoter-EF1α-2xNLS-Cascade+Cas3(RD)-iPA (expressing puromycin resistance gene), pPV-Dual_promoter-EF1α-2xNLS-Cascade+Cas3(RD)-iZA (expressing zeocin resistance gene), and pPV-Dual_promoter-EF1α-2xNLS-Cascade+Cas3(RD)-iCA.(Expressing mCherry), pPV-TRE3G-Bi(263+751)-EF1a-Tet3G-iPA (DOX-inducible, expressing puromycin resistance gene). For crRNA expression plasmids, use pBSIIKS-U6-crRNA or pPV-C1-crRNA vectors that express precursor crRNA under the U6 promoter (also including vectors that simultaneously express EGFP or the resistance gene via EF1α). When using SSA reporter molecule sorting, use pPV-EF1a-EGxxFP-iPA, pPV-EF1a-EGxxFP-iBA, pPV-EF1a-mRxxFP-iPA, pHL-EF1a-EGxxFP-iPA, pHL-EF1a-mRxxFP-iPA, pHL-EF1a-Puro-SSA-A, or pHL-EF1a-EGFP-IRES-Puro-SSA-A containing the appropriate target sequence. When selecting a drug (purinomycin, methimazole, zeocin), cells are cultured in a medium containing any concentration of the drug 1-3 days after transfection. Cells are recovered for genomic DNA and protein extraction or FACS (fluorescence-activated cell sorting) analysis. When introducing RNA via electroporation, 3 × 10⁵ cells are treated with the 4D-Nucleofector (LONZA) P4 Primary Cell 4D-NucleofectorX Kit S and operated using the CA-189 electroporation program.

[0252] In the case of multiple transfections, after transfection using the above method, cells are cultured for several days according to the cytotoxicity at the time, and transfection is repeated from the initial cell seeding. Considering the cell proliferation rate, transfection conditions, and sensitivity to transfection, the transfection interval is generally adjusted between 3 and 15 days. Additionally, during multiple transfections, cells may be temporarily frozen and then thawed for retransfection.

[0253] The presence of genome editing was determined by PCR, and the editing efficiency was determined by HLA staining to determine whether Cas3-induced deletion mutations were induced. Conventional PCR was performed on the HLA-A*24:02 gene (Figure 19), while allele-specific PCR was performed on the DMPK gene using allele-specific primers designed for heterozygous SNPs (Figures 35, 36). Additionally, nested PCR was used to improve detection sensitivity (Figures 38-47). LA Taq HS (TaKaRa) or KOD One (TOYOBO) was used as the PCR enzyme. The PCR primers used are listed in Table 2 below.

[0254] When the human B2M gene is used as the target for genome editing, the gene knockout efficiency is calculated by HLA-A / B / C staining on the cell surface. After genome editing, cells are cultured for a period of time (preferably 3-4 days or more after HLA molecules have disappeared from the cell surface), and then isolated and recovered using trypsin (including trypsin alternatives such as TrypLE Select). The recovered cells are washed with PBS and stained in 2% FBS / PBS with 50-100 times diluted anti-HLA-A / B / C antibodies (iPS cells: BioLegend Pacific Blue anti-human HLA-A, B, C antibody; HEK293T cells: BD BV421 mouse anti-human HLA-A2) (on ice for 30 minutes). HLA-stained cells are analyzed by flow cytometry to calculate the percentage of HLA-negative cells.

[0255] [Table 2] DNA samples were analyzed using a High Sensitivity D5000 ScreenTape kit via an Agilent 2200 TapeStation or an Agilent 4200 TapeStation. The proportion of DNA with deletion mutations was calculated using the TapeStation software as the proportion of DNA with a size of 400-3700 bp.

[0256] The SSA reporter vector was constructed by dividing the reporter genes EGFP, mRFP, and PuroR into two parts, adding sequences to make them homologous to each other by about 150-350 bp, and then adding two restriction enzyme sites (AfeI or Esp3I sites) for inserting the target sequence. These segmented reporter genes were inserted into a vector with pHL-EF1a or pPV-EF1a as the backbone. CrRNA target sequences of arbitrary length were inserted between the segmented reporter genes through restriction enzyme digestion and an In-Fusion reaction.

[0257] SSA reporter vector-mediated cell sorting: In the case of cell sorting using SSA reporter vectors, vectors expressing Cas3 and Cascade proteomes and vectors expressing crRNA were added to the cells, and the SSA reporter vectors were transfected. When the reporter gene of the SSA vector was Puro-SSA, cell sorting was performed by culturing in a medium containing puromycin. When the reporter gene used EGFP or mRFP fluorescent proteins, cells were recovered after transfection using trypsin (or trypsin alternatives), and EGFP and mRFP positive cells were isolated using a BD FACSAria II (BD) cell sorter.

[0258] Single-cell cloningTo isolate subclones of iPS cells that have undergone genome editing, extreme dilution or colony selection methods were used (Figure 36). When using an SSA vector utilizing fluorescent proteins EGFP and mRFP, single-cell sorting was performed in the wells of a 96-well plate pre-coated with iMatrix-511 silk when sorting EGFP and mRFP double-positive cells. The isolated cells were expanded and recovered for cryopreservation and genomic DNA extraction. PCR amplification of the target region was performed using primers in Table 2 or Table 3 below for genotyping. Sanger sequencing was performed to analyze deletion patterns.

[0259] [Table 3] Specification 38 / 49 pages 41 CN 121195066 A Quantification of genome deletion by ddPCR assay To determine the copy number of genomic DNA, ddPCR probes and primer pairs were designed using Primer 3 Plus (https: / / www.bioinformatics.nl / cgi-bin / primer3plus / primer3plus.cgi) software. To detect target genomic regions (B2M gene, dystrophin exon 44-55 locus, etc.), DNA probes labeled with 5'-6-FAM fluorophores and 3'-BHQ1 were used. Reference probes used primers labeled with 5'-HEX fluorophores and 3'-BHQ1. All primer pairs and probes are shown in Table 4 below.

[0260] [Table 4-1] Specification 39 / 49 pages 42 CN 121195066 A [Table 4-2] Specification 40 / 49 pages 43 CN 121195066 A [Table 4-3] Specification 41 / 49 pages 44 CN 121195066 A First, the isolated genomic DNA was digested overnight at 37°C using EcoRI restriction enzyme (TaKaRa). Next, the ddPCR reaction solution was prepared by mixing 11 μL of ddPCR Supermix for Probes (No dUTP) (Bio-Rad Laboratories), 1 μL of 20 μM target forward and reverse primer pairs and 0.6 μL of 10 μM target probe, 1 μL of 20 μM reference forward and reverse primer pairs and 0.6 μL of 10 μM reference probe, and EcoRI-digested genomic DNA. The total volume was adjusted to 22 μL with ultrapure water. Droplets were generated using a QX200 droplet generator or a QX200 automated droplet generator (Bio-Rad Laboratories), and the PCR reaction was performed using a C1000 thermal cycler (Bio-Rad Laboratories). ddPCRThe reaction was carried out under the following three thermal conditions. Step 1: 95℃, 10 minutes; Step 2: 94℃, 30 seconds; Step 3: 55~60℃, 1~2 minutes; Steps 2 and 3 were repeated 40 times; Step 4: 98℃, 10 minutes; Step 5: stored at 4℃. After the PCR reaction, the fluorescence of the droplets was measured using a QX200 droplet reader (Bio-Rad Laboratories), and analyzed using Bio-Rad QuantaSoft software.

[0261] Statistical analysis of the two groups was performed using Prism 8 software, and the results were calculated using the Student t-test (two-tailed, unpaired).

[0262] Example 1: Chemical modification of crRNA in RNA-based Cas3 genome editing Specification 42 / 49 pages 45 CN 121195066 A Among the experimental cancer cell lines commonly used in the biological and medical fields, many, such as HEK293T cells, have high gene introduction efficiency and are often used as model lines for genome editing. However, the gene introduction efficiency of iPS cells or primary cultured cell lines intended for regenerative medicine and other applications may not be high, and the number of cell lines selected for clinical use is inherently small, making it difficult to always choose the most suitable line for gene introduction. For this reason, it is important to develop stable and efficient genome editing methods even for cell lines with low gene introduction efficiency. Therefore, the inventors chemically modified crRNA and verified the genome editing efficiency based on this modification. First, mRNAs expressing a total of six proteins (Cas3, Cse1, Cse2, Cas5, Cas6, Cas7) were integrated with a 2A peptide that allows one mRNA to express multiple proteins, resulting in two mRNAs in the form of Cse2-P2A-Cas6-T2A-Cas3 and Cas7-P2A-Cas5-T2A-Cse1. In addition to the 5' cap and Poly A tail, the mRNA underwent base modification with 5-methylcytosine and pseudouracil (TriLink was also used in the embodiment of Patent Document 3) to inhibit cytotoxicity caused by innate immune responses and improve translation efficiency. Next, to analyze the protein expression levels and expression time of these mRNAs in iPS cells, genes were introduced into I01s04 and I14s14 iPS cell lines using Lipofectamine Stem reagent. For comparison, the pPV-Dual_promoter-EF1a-2xNLS-Cascade+Cas3(RD)-iPA plasmid vector (also used in previous patents) expressing all six proteins was introduced using Lipofectamine Stem reagent. Proteins were analyzed using Western blotting with an anti-2A peptide antibody (detection...).Cse2, Cas5, Cas6, and Cas7). The results showed that the expression level was higher than that of proteins using plasmid vectors (Figure 2). However, the expression time peaked at 8 to 24 hours after introduction and converged after 48 hours. From the above, it can be seen that when using mRNA in iPS cells, the Cas3 and Cascade proteomes can be expressed at a high intensity in a short time.

[0263] Next, regarding crRNA, unmodified crRNA synthesized previously through in vitro transcription was introduced into cells for activity evaluation (Patent Document 3). However, despite the high expression of the Cas3 and Cascade proteomes through mRNA, the genome editing efficiency was still only a few percent, suggesting that the introduced crRNA failed to play an effective role. Therefore, it was considered whether it was possible to improve the genome editing efficiency by chemically modifying specific regions of the precursor crRNA to inhibit RNase degradation of RNA. However, RNA modification can change the physical properties or secondary structure of RNA, its interaction with proteins, and may also lose its original function. Even experts cannot predict what kind of modification to introduce at what location, which is the reality. Therefore, the inventors introduced 2'-O-methyl 3'-thiophosphate modification (MS modification) into the precursor crRNA of the Escherichia coli CRISPR-Cas3 system and studied the modification sites that enhance activity. As a result, it was found that by MS modification of the three bases at both ends of the precursor crRNA, its function was not lost and the genome editing efficiency was significantly improved (Figures 3-1 to 4-2). This confirms that it is independent of the two iPS cell lines I01s04 and I14s04, and the gene introduction method is also independent of lipid transfection (Lipofectamine Stem reagent) or electroporation (4D-Nucleofector). Surprisingly, if the modification was performed at the end of the mature crRNA produced after the precursor crRNA was cleaved by Cas6, i.e. (2) or (3), the activity was observed to be comparable to or reduced compared to the unmodified one (Figures 4-1, 4-2). Therefore, modification is not possible at any location, and it can be said that the modification sites that enhance activity are limited.

[0264] Next, the activity changes caused by the modification sites were studied in more detail. Precursor crRNA with modifications at the positions shown in Figures 5-1 to 5-4 was introduced into cells via lipid transfection, similar to the method described above. As a result, genome editing efficiency was improved by introducing modifications into the loop portions of the two end regions (bilateral) and the two stem-loop forming regions. Furthermore, genome editing efficiency was improved in the central region (i.e., the 3' lateral stem-forming region of the first repeat sequence (left right stem), the 3' arm region of the first repeat sequence (left right arm), the 5' arm region of the second repeat sequence (right left arm), and the 5' lateral stem-forming region of the second repeat sequence (right left stem)).The genome editing efficiency tended to decrease or remain almost unchanged due to the introduction of modifications (Figure 6-1). Furthermore, at the Cas6 cleavage site, the genome editing efficiency was significantly reduced upon the introduction of modifications. Surprisingly, although the precursor crRNA has a nearly symmetrical structure, the genome editing efficiency tended to increase upon the introduction of modifications to the 5' side regions (specifically, the 5' end region (Pre-5'), the 5' arm region of the first repeat sequence (left arm), the 5' stem-forming region of the first repeat sequence (left stem), and the loop-forming region of the first repeat sequence (left loop)) and the 3' arm region of the second repeat sequence (right arm). On the other hand, the genome editing efficiency tended to be almost unaffected upon the introduction of modifications to the 3' side regions (specifically, the 3' end region (Pre-3') and the 3' stem-forming region of the second repeat sequence (right arm)). This suggests that the modification effect of the precursor crRNA exhibits left-right asymmetry. Furthermore, if the precursor crRNA is cleaved by Cas6, the 3' arm region of the first repeat of the precursor crRNA becomes the 5' end of the cleaved (mature) crRNA, but no improvement in genome editing efficiency was found by introducing modifications into this arm region. That is, there is a difference in the effect of introducing modifications between precursor crRNA and mature crRNA.

[0265] The effect of precursor crRNA modification in another iPS cell (1383D2) was verified. Genome editing efficiency was evaluated by ddPCR using precursor crRNAs targeting B2M (Fig. 6-2) or DMD EX45 (Fig. 6-3). These results showed that the effect of precursor crRNA modification patterns could still be reproduced even if the iPS cell type or the target gene of genome editing was changed. In addition, it was also shown that genome editing efficiency was reduced by introducing modifications into the nucleotides of the spacer region (“target” in Fig. 6-3).

[0266] Next, it was investigated whether the activity of precursor crRNA could be improved by methods other than chemical modifications of RNA bases and backbone. Therefore, we attempted to add a 5'-cap analogue (ARCA) and a Poly A tail to the precursor crRNA, similar to the addition of mRNA (Figures 7 and 8). Results in HEK293T cells (Figure 9) and I14s04iPS cells (Figure 10) showed that adding a 5'-cap and a Poly A tail also increased the activity of the precursor crRNA. Furthermore, cell lines highly sensitive to gene introduction often fail to achieve ideal genome editing efficiency in a single genome editing session. In such cases, repeated gene introductions can accumulate the genome editing effect (Figure 11). In genome editing experiments using a standard CRISPR-Cas9 system, the target sequence...The introduction of deletions or mutations is basically a one-time introduction, but in the CRISPR-Cas3 system, a large deletion is introduced on the PAM sequence side of the target sequence, but the target sequence of the crRNA is often preserved. Therefore, it is speculated that by introducing the same crRNA into the same cell multiple times, the cutting efficiency can be improved.

[0267] Example 2: Analysis of deletion mutation patterns using ddPCR In order to make genome editing a practical technology, it is necessary to accurately analyze what kind of DNA mutations can be induced by this technology and the mutation (cutting) induction efficiency. Unlike Cas9, which specifically induces the cutting of small double-stranded DNA, Cas3 is known to induce various long chain deletions of different lengths, but a simple method to analyze the proportion and length of deletion mutations has not yet been developed. Therefore, the inventors attempted to develop a technique to determine the length distribution and proportion of deletion mutations caused by Cas3 by applying droplet digital PCR (ddPCR) technology. First, the idea of ​​designing multiple ddPCR probes at various positions around the target sequence and directly measuring the copy number at each position in the genomic DNA of the genome-edited cells was conceived (Figure 12). This method allows analysis of the proportion and length of mutations induced by the used crRNA in the actual target genome sequence, which is very useful for designing crRNA or studying its activity. In fact, genome editing of the B2M gene (using B2M#1 as crRNA) was performed using HEK293T cells, whose Cas3 and Cascade proteome expression can be regulated by doxycycline (DOX). The results showed changes in editing efficiency based on DOX concentration or treatment time (Figure 13). This analysis revealed that a certain proportion of deletion mutations were introduced in the opposite direction to the Cas3 direction (the PAM side of the crRNA). Furthermore, the same experiment was performed in CiRA00213iPS cells, successfully analyzing deletion patterns (Figure 14). Interestingly, when using the RNA-based CRISPR-Cas3 system for genome editing (Figure 15 top), the proportion of long-chain deletions greater than 10kb was observed to be lower than when DOX-induced Cas3 and Cascade proteome expression was induced over several days (Figure 15 bottom). As shown in Figure 2, the expression time is short when the protein is expressed by mRNA, thus suggesting a difference compared to other methods that can maintain a longer expression time.

[0268] Due to the complexity of the Cas3 genome editing mode, it is difficult to hypothesize or predict what deletion patterns will occur when multiple crRNAs are used. This assay using ddPCR can analyze not only genome editing using one crRNA, but also the deletion mutation patterns shown when multiple crRNAs are used. For example, on the dystrophin gene, as per the specification pages 44 / 49, 47 CN 121195066When configuring two crRNAs in the A-pair configuration, the extent of copy number reduction at the midpoint can be analyzed (Figure 16). In more complex cases, copy number changes at seven positions can be measured when configuring 4–11 crRNAs (Figure 17). Furthermore, when designing new crRNAs, their activity can be evaluated, and the degree of deletion in any region of the target gene can be assessed. In knocking out HLA-A (A*24:02) and B (B*52:01) in I14s04iPS cells, ideally, functionally important exons 1–3 (especially exon 2) should be deleted (Figure 18). Various crRNAs can be designed to achieve this goal; however, as a post-genome editing analysis, while existing PCR methods can confirm activity in the target region, they often cannot determine the strength of that activity. This is because, especially when the designed crRNA is located in different positions and orientations, the position and length of the deletion mutation induced by Cas3 vary, and the ladder-like bands of the deletion shown by PCR also change, resulting in a loss of quantification (Figure 19: using Lipofectamine Stem, Cas3 and Cascade proteomes are expressed by mRNA, and crRNA is expressed by plasmid). The inventors designed ddPCR probes / primers on exons 2 of the HLA-A and B genes, and analyzed the activity intensity by measuring the deletion efficiency of exons 2 of several crRNAs. For I14s04iPS cells, Lipofectamine Stem was used to transfect Cas3 and Cascade proteome mRNA and MS-modified precursor crRNA (Figure 5-1 Pre-both3) three times. First, successful genome editing was confirmed using the control crRNA (B2M#1) which had shown activity (Figure 20, left). Next, the activity of three Pre-both3 precursor crRNAs (A24 F1, R2, R4 and B52 F1, R5, R7) for HLA-A and B was measured by ddPCR. The results showed that all crRNAs were active, but the intensity of their activity varied (Fig. 20, right). This difference in activity could not be determined using existing PCR methods (Fig. 19). Furthermore, to simultaneously knock out both HLA-A and B genes, genome editing was performed using two crRNAs targeting HLA-A24 and B52, respectively. In this case, the deletion efficiency of exon 2 for HLA-A and B could be measured (Fig. 21).

[0269] Thus, this assay technique, by changing the position of the ddPCR probe according to the purpose, is useful for various evaluations such as analyzing deletion patterns, evaluating the activity of designed crRNAs, and measuring the proportion of mutations induced in the opposite direction to the target.

[0270] Example 3: Enrichment of Cell Populations for Genome Editing Using SSA Reporter Vectors with the CRISPR-Cas3 System. When using the type I CRISPR-Cas3 system as a genome editing tool, the large number of required factors (7 factors in total, 6 proteins and crRNA) means that even insufficient expression of just one factor in the cell can prevent genome editing, posing a problem from the perspective of achieving effective genome editing. Therefore, the inventors have developed a technique that can specifically enrich cell populations where Cas3 is activated due to the sufficient expression of these essential factors. It has been reported that for Cas9, reporter vectors utilizing the DNA repair mechanism of single-strand annealing (SSA) are used to enrich genome-edited cells by sorting Cas9-activated cells. However, unlike Cas9, which only involves simple double-strand DNA cleavage, Cas3, which involves long-strand DNA cleavage, requires the design of suitable reporter vectors.

[0271] Therefore, the inventors designed an SSA reporter vector (Figure 22) based on fluorescent proteins (EGFP or mRNP, etc.) and drug resistance genes (PuroR, etc.), and explored the most suitable insertion sequences for the CRISPR-Cas3 system. First, since Cas3 causes long chain deletions in a single direction, it was considered that even the reporter gene might be deleted due to Cas3 if only a very short sequence such as the recognition sequence of crRNA was inserted. Therefore, the activity of the CRISPR-Cas3 system with longer insertion sequences of 0.5 kb, 1 kb, or 2 kb was evaluated using the SSA vector. In this case, the reporter gene was mRFP. Using the HEK293T stable expression strain, which can induce Cas3 and Cascade proteome expression via DOX, crRNA expression vectors (non-target: AAVS1#1, target: DownSNP1T) and mRFP SSA vectors (with DownSNP1T as the target insert sequence, the length of which is 0.5~2kb: pPV-EF1a-mRxxFP-iPA) were transfected with Lipofectamine 2000. Three days later, the proportion of mRFP-positive cells was analyzed by flow cytometry. The results showed that, compared with the use of non-target crRNA, a higher reporter signal was obtained when using target crRNA (Figure 23). It is evident that the longer the insert sequence, the lower the background signal tends to be; however, for a 2kb insert sequence, a decrease in target signal was also observed. As indicated by the S / N ratio, it can be said that, under these experimental conditions, insert sequences of approximately 1kb are suitable for Cas3.

[0272] Using the SSA vector developed for this CRISPR-Cas3 system, the possibility of enriching actual gene-generating bases was then investigated.Cells undergoing genome editing were used. SSA vectors (pHL-EF1a-EGFP-IRES-Puro-SSA (B2M 1kb)-A vector) with PuroR as the reporter gene were designed to induce puromycin resistance in Cas3-activated cells. Genome editing targeting the B2M gene was performed in HEK293T cells (transfection with pPV-Dual_promoter-EF1a-2xNLS-Cascade+Cas3(RD)-iCA and pPV-C1-crRNA(B2M#4)-EF1a-BA vectors). The Puro-SSA vector was introduced simultaneously, followed by puromycin selection (2 μg / ml, 3-5 days post-transfection). The genome editing efficiency of these samples was determined by HLA staining, showing a significantly higher (approximately 6-fold) efficiency compared to samples without puromycin selection (Figure 24). This demonstrates that SSA vectors in the CRISPR-Cas3 system can enrich cells that have undergone genome editing. Next, the specificity of the Puro-SSA vector was verified. Using Lipofectamine 2000, Cas3 and Cascade proteome expression vectors (the same as described above), crRNA expression vectors (non-target: AAVS1#1, target: B2M#1 pPV-C1-crRNA-EF1a-BA vector), and the Puro-SSA vector with the target sequence B2M#1 (pHL-EF1a-Puro-SSA(B2M 1kb)-A) were introduced into HEK293T cells. Cells were treated with 2 μg / ml puromycin for 2 days from day 2 to day 4 after introduction. Cell counts were performed on day 6 after vector introduction, confirming a significant increase in Puro-resistant cells in cells with introduced crRNA (B2M#1), thus confirming the specificity of the Puro-SSA vector for crRNA (Figure 25). Furthermore, the knockout efficiency of B2M in these samples was measured, showing that Puro selection could enrich the genome-edited cells by approximately 10-fold (Figure 26).

[0273] This SSA vector can also be used in combination with multiple different reporter genes (EGFP and mRFP, etc.), and can also be applied to genome editing using multiple crRNAs simultaneously (Figure 27). For example, in the case of inducing multi-exon skipping that results in the deletion of exon 45-55 (approximately 340kb) of the human dystrophin (DMD) gene using the treatment of Dechene muscular dystrophy as a model, even if the two crRNAs are designed to be relative (crRNAs targeting Ex45 and Ex55), the deletion efficiency predicted from the copy number at approximately the midpoint is still low due to the wide deletion range (Figure 29: SSA unsorted). However, it is also possible to use a vector containing these two crRNAs simultaneously.EGFP / mRFP double-positive cell populations were sorted using EGFP and mRFP-based SSA vectors targeting the sequence, thereby enriching cells with a deletion of approximately 340 kb. First, in experiments in HEK293T cells where the length of the target insert sequence was varied, as in Figure 23, a reduction in both specific and non-specific signals was observed as the insert sequence length increased (Lane 1-6, left, Figure 28). Subsequently, an SSA vector with an insert sequence of approximately 1 kb was chosen, as this insert sequence could suppress non-specific signals as much as possible without reducing specific signals. Next, EGFP·mRFP double-positive cells were actually sorted using a two-color SSA vector with a 1 kb insert sequence, and the copy number deletion efficiency at approximately the midpoint of the 340 kb deletion was determined by ddPCR. The results showed a copy number reduction of approximately 6%–40% in HEK293T cells and approximately 0%–30% in F12020 iPS cells compared to unsorted cells (Lane 1-3, left, Figure 29). Compared to Cas9, which can only induce small double-strand cuts, the enrichment efficiency of cells was poor (lanes 6-9, left, Fig. 29), indicating that this SSA vector with long insert sequences is suitable for Cas3, which can induce long deletions. Moreover, using this two-color SSA vector system, cells with edited genomes were enriched from various iPS cell lines (FF12020, CiRA00458, CiRA00646), and multiple subclones carrying deletion mutations of approximately 340 kb were successfully obtained (Fig. 30). It is known that this multi-exon skipping method that deletes the 45-55 region of exons can restore the reading frame of dystrophin, which is also useful as a treatment for Dystrophin muscular dystrophy.

[0274] Finally, the S / N ratio was compared with that of existing SSA vectors with short insert sequences. Assuming that the DMD gene of approximately 340 kb was deleted by Cas3 in HEK293T cells as described above, when using both crRNA (DMD20) and crRNA (DMD23) simultaneously, the length of the insert sequence of the SSA vector was extended to 0 kb (i.e., target sequence only), 0.5 kb, 1 kb, and 1.7 kb. It was found that the nonspecific signal was significantly reduced with the longer insert sequence (Fig. 31). On the other hand, if the insert sequence became longer, a reduction in the target signal was also observed. Based on these results, it can be concluded that the S / N ratio reaches its maximum when the insert sequence is approximately 1 to 1.7 kb.

[0275] In addition to utilizing this long insert sequence, the idea of ​​applying the mechanism of inducing double-strand cutting through DNA double nicking to this SSA vector was conceived, considering that Cas3 is a single-stranded DNA cutting enzyme, i.e., a nicking enzyme (Fig. 27 right).In this SSA vector, the two crRNA recognition sequences were arranged in a palindromic sequence. Considering the steric hindrance in Cas3 and Cascade binding, a spacer sequence of 0–35 bp was inserted between these two recognition sequences. Similarly, using two crRNAs targeting DMD Ex45 and Ex55 (as a non-target control, B2M#1), experiments were conducted using a two-color, double-cut SSA vector (EGFP: Ex45, mRFP: Ex55) containing these target sequences. The results showed higher on-target signals, namely EGFP and mRFP fluorescence, compared to when using non-target crRNAs (Figure 28, lanes 7–10). Among these, when sorting EGFP and mRFP double-positive cells using a double-cut SSA vector without a spacer region, and measuring the copy number reduction by ddPCR, the proportion of copy number reduction increased from approximately 5% to approximately 40% compared to unsorted samples (Figure 29, left lanes 4–6).

[0276] The results above show that by using this SSA vector (long insert sequence and double-cut insert sequence), cells with active Cas3 / crRNA can be monitored or enriched.

[0277] Example 4: Allele-specific genome editing technology based on CRISPR-Cas3 system Genes on autosomes are usually composed of two copies in pairs, but in the treatment of genetic diseases, allele-specific genome editing technology that targets only a single allele is also important. For example, myotonic dystrophy type I (DM1) is a genetic disease caused by the abnormal extension of the CTG repeat in the 3'-UTR region of the DMPK gene in only a single allele. In the case of treatment by genome editing, it is desirable to edit only the repeat sequence of this extended allele (pathogenic allele) without touching the unaffected allele (normal allele). Therefore, the inventors have focused on heterozygous single nucleotide polymorphisms (SNPs) and developed a CRISPR-Cas3 system technology that can delete only the extended CTG repeat in the pathogenic allele. First, SNPs with high allele frequency were searched in the SNP database, and the actual presence of these SNPs was confirmed in iPS cells from multiple DM1 patients (Figure 32).

[0278] Next, crRNAs that could be designed on these SNPs were screened. AAG, ATG, TAG, AGG, GAG, AAC, AAT, AAA, GTG, TTG, and GGG were used as protospacer adjacent motif (PAM) sequences, and heterozygous SNP sequences were located on sequences recognizable by crRNA (6n from the 3' end of the PAM sequence (n is positive)).The location is outside the integer number of bases, and it is in the direction that Cas3 moves towards the CTG repeat (Fig. 33). As a practical example of such a crRNA, a crRNA was designed targeting the rs934739524 SNP (C: pathogenic allele, T: normal allele) downstream of the CTG repeat found in the HPS1051 iPS cell line from DM1 patients (Fig. 34). The control crRNA with a heterozygous SNP located at the 12th base of the crRNA is an allele that cannot be distinguished (is difficult to distinguish). The results of genome editing using this crRNA in the HPS1051 iPS cell line from DM1 patients (a stable expression line expressing Cas3, Cascade proteome, and crRNA expression vector) successfully resulted in preferential deletion mutations at the target allele (Fig. 35). In addition, to confirm whether genome editing actually occurred on the target alleles, cell subcloning of this cell population yielded several strains that actually only lacked the CTG repeat in the pathogenic allele (Fig. 36: clones #9, 19, 20, 33, 84). As another example, crRNAs were designed targeting the upstream SNPs rs635299 and rs915915 of the CTG repeat found in the CiRA00213 iPS cell line from DM1 patients (Fig. 37). In both RNA-based genome editing (mRNA and Pre-both3 precursor crRNA) and plasmid-based genome editing, Sanger sequencing analysis of PCR products obtained by allele-specific PCR or nested PCR confirmed the deletion or shortening of the CTG repeat (plasmid-based genome editing: Figs. 38-41, RNA-based genome editing: 42, 43). In addition, this allele-specific genome editing can also be performed using two heterozygous SNPs, using a pair of crRNAs sandwiching the target sequence (allele-specific double Cas3). In CiRA00213 strain, for example, even using crRNA designed on rs635299 upstream of the CTG repeat and crRNA designed on rs3745802 downstream (RNA-based editing: Figure 44), or using crRNA on rs915915 upstream of the repeat and crRNA on rs3745802 downstream (RNA-based editing: Figures 45, 47, plasmid-based editing: Figure 46), genome editing can be performed.

[0279] Thus, by configuring heterozygous SNPs at crRNA recognition sequence sites, allele-specific crRNAs can be designed, and their activity or specificity can be confirmed using an SSA reporter vector (Figure 48 left). For example, in an EGFP and mRFP two-color SSA vector, genome editing can be performed.Using an insertion sequence that differs by one base from the target sequence of the crRNA, the signaling of EGFP and mRFP was analyzed. As crRNAs, crRNAs targeting "C" in rs934739524 (crRNA-C), crRNAs targeting "T" (crRNA-T), and non-targeting crRNAs (NT crRNA) were used. Sequences containing "C" or "T" were inserted into the EGFP SSA vector and the vector, respectively. When fluorescence was measured, the fluorescence of the crRNA-targeted SSA vector was observed preferentially (Fig. 48 right). These SSA vectors, when combined with cell sorting, are expected to be used to enrich cells with genome editing activity.

[0280] Although the activity or specificity of the designed allele-specific crRNA is predicted to vary depending on its sequence, these properties can be modified to some extent. Examples of such methods include shortening the length of the crRNA or intentionally introducing mismatches at positions far from the PAM (Fig. 49). For example, in the above-mentioned crRNA targeting the "C" of the rs934739524 SNP, in experiments where EGFP SSA has a "C" target and mRFP SSA has a "T" target, the activity slowly decreased as the crRNA length was shortened (Fig. 50) or the intentional mismatch was moved closer to the PAM (Fig. 51). However, non-specific activity (mRFP signal) was also found to decrease. In the case of this crRNA, when the crRNA recognition sequence was 30 nt long and there was a mismatch at the second base from the 3' of the crRNA recognition sequence, the activity against the target remained unchanged, and non-specific activity was successfully reduced. Thus, it can be said that adjusting the length of the crRNA recognition sequence or introducing an intentional mismatch to allele-specific crRNA effectively regulates the activity and specificity of the crRNA.

[0281] Example 5: Chemical Modification of crRNA Based on Protein Structure Based on the crystal structure of *E. coli* Cascade / crRNA (Zhao et al., *Nature*, Vol. 515, 147-150 (2014), Jackson et al., *Science*, 345(6203), 1473-1479 (2014), the sites shown in Figure 52 that could potentially undergo 2'-O-Me (M) or phosphate thioester (PS) modification were modified (structure-guided: SG). Furthermore, it is known that modification of the three bases at both ends of the precursor crRNA is not a problem, therefore these were added to the SG (SG + edge 3). Additionally, cases of PS or M modification of all bases (all PS, all M) or at least no PS modification of the Cas6 processing site (PS except for the cleavage site) were prepared.

[0282] Using the aforementioned precursor crRNA, genome editing activity was measured in I14s04iPS cells. 1.5 × 10⁵ cells were seeded in 12-well plates and transfected with mRNA expressing Cas3 and Cascade proteins, and B2M#1 crRNA (each with chemical modifications corresponding to those in Figure 52). The knockout efficiency of the B2M gene was determined by HLA-A, B, and C staining (Figure 53) or ddPCR (Figure 54). ddPCR used the B2M_1kb / PATL2 probe. The results showed that even if the sites interacting with the Cascade complex were identified based on the crystal structure, it was difficult to predict the location of the chemically modified precursor crRNA.

[0283] Among the SG+#3 crRNAs for which no activity was confirmed in Figures 53 and 54, further investigation was conducted on modification patterns, focusing on which site modifications would adversely affect activity. The following types of modifications were created in the precursor crRNA: (SG+side3-A) with the modification near the Cas6 processing site removed; (SG+side3-A-target) with the modification further removed from the target sequence recognition site removed; (SG+side3-A-inner arm) with the modification removed from the inner arm portion of SG+side3-A; (SG+side3-A-center) with the modification removed from both the inner arm portion and the target sequence recognition site removed from SG+side3-A; (side3+loop+left stem) with simultaneous modification of the terminal 3 bases, 2 loops, and left repeat of the left stem sequence, which enhances activity; and (side3+target) with the modification of the terminal 3 bases added. These were transfected into I14s04iPS cells, and the KO efficiency of the B2M gene was determined by HLA-A, B, and C staining. The results showed that adding modifications to the inner arm portion and the target sequence recognition site adversely affected activity. Instruction manual, pages 48 / 49, 51 CN 121195066 A

[0284] Example 6: Determination of HLA-A*24:02 and B*52:01 exon 2 deletion efficiency by ddPCR In I14s04iPS cells, mRNA expressing Cas3 and Cascade proteomes and Pre-both3 precursor crRNA targeting HLA-A*24:02 and B*52:01 were transfected multiple times using Lipofectamine Stem (Figure 5-1). The recovered genomic samples were analyzed by ddPCR. “Double A24 F1 & B52 R5” indicates tandem precursor crRNA with MS modification of the two ends of 3 bases. The target sequence information of the crRNA used in this example is shown in Table 5.

[0285] [Table 5] Example 7: Evaluation of the effect of Puro-SSA vector in 1383D4 iPS cells0.5 × 10⁵ cells were seeded in 12-well plates and transfected with mRNA expressing Cas3 and Cascade proteins, B2M#1 crRNA (MS modified at both ends of 3 bases), and pHL-EF1a-Puro-SSA(B2M#1)-A or pHL-EF1a-Puro-SSA(B2M#1)-2A-EGFP-A as a Puro-SSA reporter vector. Puro-mediated selection was performed on day 2-3 post-transfection at a concentration of 0.3 or 0.5 μg / ml. After cell recovery, the proportion of HLA-A, B, and C negative cells was determined by HLA-A, B, and C staining. Typical flow cytometry results and quantitative graphs (n=2) are shown in Figure 59. The results showed that B2M knockout cells could be enriched by about 2-4 times.

[0286] Industrial Applicability According to the present invention, the genome editing efficiency of the type I CRISPR-Cas system can be improved, and the genome editing mode of the system can be analyzed. In addition, it can also be used as a tool for enriching genome editing cells or for specific genome editing of single alleles. Therefore, it is particularly useful for genome editing of pluripotent stem cells, which is difficult to achieve with existing methods.

[0287] This application is based on Japanese Patent Application No. 2023-050681 (application date: March 27, 2023), the contents of which are fully contained in this specification. Instruction manual page 49 / 49 52 CN 121195066 A Figure 1 Figure 2 Instruction manual drawing page 1 / 40 53 CN 121195066 A Figure 3-1 Instruction manual drawing page 2 / 40 54 CN 121195066 A Figure 3-2 Instruction manual drawing page 3 / 40 55 CN 121195066 A Figure 4-1 Figure 4-2 Instruction manual drawing page 4 / 40 56 CN 121195066 A Figure 5-1 Figure 5-2 Instruction manual drawing page 5 / 40 57 CN 121195066 A Figure 5-3 Figure 5-4 Instruction manual drawing page 6 / 40 58 CN 121195066 A Figure 6-1 Figure 6-2 Instruction manual drawing page 7 / 40 59 CN 121195066 A Figure 6-3 Figure 7 Instruction manual drawing page 8 / 40 60 CN 121195066 A Figure 8 Figure 9 Appendix to the Instruction Manual 9 / 40 Page 61 CN 121195066 A Figure 10 Appendix to the Instruction Manual 10 / 40 Page 62 CN 121195066 A Figure 11 Figure 12 Appendix to the Instruction Manual 11 / 40 Page 63 CN 121195066 A FigureFigure 13 Figure 14 Appendix to the Instruction Manual, Page 12 / 40, 64 CN 121195066 A Figure 15 Figure 16 Appendix to the Instruction Manual, Page 13 / 40, 65 CN 121195066 A Figure 17 Appendix to the Instruction Manual, Page 14 / 40, 66 CN 121195066 A Figure 18 Appendix to the Instruction Manual, Page 15 / 40, 67 CN 121195066 A Figure 19 Figure 20 Appendix to the Instruction Manual, Page 16 / 40, 68 CN 121195066 A Figure 21 Figure 22 Appendix to the Instruction Manual, Page 17 / 40, 69 CN 121195066 A Figure 23 Figure 24 Appendix to the Instruction Manual, Page 18 / 40, 70 CN 121195066 A Figure 25 Figure 26 Appendix to the Instruction Manual, Page 19 / 40, 71 CN 121195066 A Figure 27 Figure 28 Appendix to the Instruction Manual, Page 20 / 40, 72 CN 121195066 A Figure 29 Figure 30 Instruction Manual Drawings 21 / 40 Page 73 CN 121195066 A Figure 31 Instruction Manual Drawings 22 / 40 Page 74 CN 121195066 A Figure 32 Figure 33 Instruction Manual Drawings 23 / 40 Page 75 CN 121195066 A Figure 34 Figure 35 Instruction Manual Drawings 24 / 40 Page 76 CN 121195066 A Figure 36 Figure 37 Figure 38 Instruction Manual Drawings 25 / 40 Page 77 CN 121195066 A Figure 39 Instruction Manual Drawings 26 / 40 Page 78 CN 121195066 A Figure 40 Instruction Manual Drawings 27 / 40 Page 79 CN 121195066 A Figure 41 Instruction Manual Drawings 28 / 40 Page 80 CN 121195066 A Figure 42 Instruction Manual Drawings 29 / 40 Page 81 CN 121195066 A Figure 43 Appendix 30 / 40 Page 82 CN 121195066 A Figure 44 Appendix 31 / 40 Page 83 CN 121195066 A Figure 45 Appendix 32 / 40 Page 84 CN 121195066 A Figure 46 Appendix 33 / 40 Page 85 CN 121195066 A Figure 47 Appendix 34 / 40 Page 86 CN 121195066 AFigure 48 Figure 49 Figure 50 Appendix to the Instruction Manual, Page 35 / 40, 87 CN 121195066 A Figure 51 Figure 52 Appendix to the Instruction Manual, Page 36 / 40, 88 CN 121195066 A Figure 53 Figure 54 Appendix to the Instruction Manual, Page 37 / 40, 89 CN 121195066 A Figure 55 Figure 56 Appendix to the Instruction Manual, Page 38 / 40, 90 CN 121195066 A Figure 57 Figure 58 Appendix to the Instruction Manual, Page 39 / 40, 91 CN 121195066 A Figure 59 Appendix to the Instruction Manual, Page 40 / 40, 92 CN 121195066 A

Claims

1. A precursor crRNA, which is a type I CRISPR-Cas system precursor crRNA with modified nucleotides. in, In the region consisting of the 5' arm region of the first repeat sequence, the 5' stem-forming region of the first repeat sequence, and the loop-forming region of the first repeat sequence, at least one nucleotide is a modifying nucleotide.

2. The precursor crRNA according to claim 1, wherein, At least one nucleotide in the 3' arm region of the second repeat sequence is a modified nucleotide.

3. The precursor crRNA according to claim 1 or 2, wherein, The first to third nucleotides from the 5' end and the second to fourth nucleotides from the 3' end are modifying nucleotides.

4. The precursor crRNA according to any one of claims 1 to 3, wherein, All nucleotides in the loop-forming region of the first repeat sequence and / or the loop-forming region of the second repeat sequence are modified nucleotides.

5. The precursor crRNA according to any one of claims 1 to 4, wherein, The first to third nucleotides from the 5' end and the second to fourth nucleotides from the 3' end are modified nucleotides. All nucleotides constituting the 3' arm region of the first repeat sequence, the 5' arm region of the second repeat sequence, and the spacer region are ribonucleotides, and the sites cleaved by Cas6 or Cas5 are unmodified.

6. The method according to any one of claims 1 to 5, wherein it has two or more interval regions.

7. The precursor crRNA according to any one of claims 1 to 6, wherein, The type I CRISPR-Cas system is the type IE CRISPR-Cas system.

8. The precursor crRNA of the type I CRISPR-Cas system, which has a 5' cap and Poly A.

9. A method for designing precursor crRNAs for allele-specific type I CRISPR-Cas systems, comprising the steps of designing precursor crRNAs targeting specific sequences. The sequence has a deletion target site upstream of the PAM sequence adjacent to the sequence targeted by the precursor crRNA, and Within the sequence targeted by the precursor crRNA, there is at least one allele-different base at a position other than the 6nth base from the downstream end of the PAM sequence, or on the PAM sequence, where n is a positive integer.

10. The method according to claim 9, comprising the steps of: adjusting the length of the precursor crRNA and / or introducing a mismatch into the precursor crRNA.

11. The method according to claim 9 or 10, wherein, The missing target site contains duplications.

12. A type I CRISPR-Cas system comprising the following (1) and (2): (1) The precursor crRNA according to any one of claims 1 to 8 or the precursor crRNA designed by the method according to any one of claims 9 to 11; and (2) The proteome that makes up Cascade or the nucleic acid that encodes the proteome.

13. A double-stranded nucleic acid for evaluating the activity of a type I CRISPR-Cas system, wherein one of the nucleic acid strands comprises the following (1) to (3): (1) A sequence encoding a portion of a reporter protein; (2) An insertion sequence containing the sequence targeted by the crRNA or a sequence complementary to that sequence; and (3) Encodes a portion of the reporter protein and a sequence different from (1), in, (1) and (3) contain repetitive sequences. The sequence of (1) excluding the repetitive sequence, the repetitive sequence, and the sequence of (3) excluding the repetitive sequence constitute the full-length sequence encoding the reporter protein. (2) The length of the inserted sequence is 100~3000 bases.

14. A double-stranded nucleic acid for evaluating the activity of a type I CRISPR-Cas system, wherein one of the nucleic acid strands comprises the following (1) to (3): (1) A sequence encoding a portion of a reporter protein; (2) An insertion sequence comprising the sequence targeted by the crRNA and a sequence complementary to that sequence; and (3) Encodes a portion of the reporter protein and a sequence different from (1), in, (1) and (3) have repetitive sequences. The sequence of (1) excluding the repetitive sequence, the repetitive sequence, and the sequence of (3) excluding the repetitive sequence constitute the sequence encoding the full length of the reporter protein.

15. A method for producing cells with altered double-stranded DNA, comprising: The process of introducing the CRISPR-Cas system of claim 12 into cells.

16. The method according to claim 15, wherein, The process of introducing the CRISPR-Cas system into cells is repeated multiple times.

17. The method according to claim 15 or 16, comprising: The process of introducing the double-stranded nucleic acid as described in claim 13 or 14 into cells.

18. The method according to claim 17, wherein, The introduced double-stranded nucleic acids are of two or more types.

19. The method according to claim 17 or 18, comprising: The process of sorting and reporting cells that express proteins.

20. The method according to any one of claims 15 to 19, wherein, The cells in question are pluripotent stem cells.

21. A method for analyzing the editing patterns of double-stranded DNA by a type I CRISPR-Cas system, comprising: The process of digital PCR using multiple PCR probes targeting missing target sites.